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 ABSTRACT 
 
ARIELLA HANKER: Ras Family GTPases Involved in Breast Cancer 
(Under the direction of Channing J. Der) 
 
 
The Ras branch of the Ras superfamily of small GTPases consists of over thirty-six 
proteins that regulate a wide array of cellular processes.  Mutations in the RAS oncogene that 
cause aberrant activation of Ras signaling drive 30% of all cancers, but these mutations are 
infrequent in breast cancer.  Instead, other Ras family proteins may play more significant 
roles in the development and progression of breast cancer.  Here, we focus on two such 
proteins, Rerg and Rheb.  Hyperactive Rheb activity may enhance breast cancer 
tumorigenesis, whereas Rerg has been proposed to negatively regulate breast cancer growth.  
Expression of Rerg is controlled by estrogen; hence, Rerg is not expressed in ERα-negative 
breast cancers.  Whether loss of Rerg expression in these tumors contributes to breast cancer 
progression is not known.  We found that silencing Rerg expression did not significantly 
enhance the growth or invasive properties of breast cancer cells, and likewise, inducing Rerg 
expression in Rerg-negative breast cancer cell lines did not diminish their growth.  Thus, 
these studies argue against a role for Rerg as a tumor suppressor in breast cancer.  More 
studies are needed to determine whether Rerg is involved in breast cancer in vivo. 
Rheb and its effector mTOR have been strongly implicated in the development of 
many cancers, including breast cancer.  Upstream regulators of Rheb are commonly activated 
in the majority of breast cancers, leading to increased Rheb activity in breast cancer.  
 ii
However, approaches to inhibit Rheb function in breast cancer have not been 
comprehensively explored.  Here, we investigated two strategies to inhibit Rheb-mTOR 
signaling.  First, we asked whether CAAX-mediated posttranslational processing of Rheb is 
required for its function.  We found that, while farnesylation is absolutely required for Rheb 
activation of mTOR, post-prenyl processing by the enzymes Rce1 and Icmt is dispensable for 
Rheb signaling.  Our studies further suggested that endomembrane localization of Rheb is not 
required for its activation of mTOR.  Finally, we found that the farnesylcysteine mimetic S-
trans, trans-farnesylthiosalicylic acid (FTS; salirasib) did not block Rheb localization, but 
potently inhibited mTOR-induced p70 S6 kinase (S6K) activation, suggesting that FTS is a 
direct inhibitor of mTOR.  Therefore, FTS may be a promising therapy for the treatment of 
Rheb- and mTOR-dependent cancers, including breast cancer.  Together, these studies have 
increased our understanding of the functions of Rerg and Rheb in breast cancer and have 
suggested a potential therapeutic strategy to reverse aberrant Rheb signaling in breast cancer. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
Targeted therapies for breast cancer.  Approximately 180,000 new cases of breast 
cancer were diagnosed in the United States in 2008 (www.cancer.gov), and despite 
significant advances in understanding the molecular pathways driving this disease, breast 
cancer remains the second leading cause of cancer-related deaths among American women, 
with more than 40,000 deaths per year.  One complication in the treatment of breast cancer is 
that this disease is not simply one disease that exhibits a common genetic basis, clinical 
progression, and outcome; hence, not all breast cancers will respond to one therapeutic 
approach.  Instead, breast cancer is comprised of at least five subtypes that are distinguished 
by distinct genetic and molecular profiles, and that exhibit differing prognoses and 
sensitivities to therapies (1-3).  
Nearly 70% of breast cancers express the estrogen receptor alpha (ERα) and depend 
on estrogen for growth.  Current therapies for ERα-positive breast cancers exploit this 
dependency on estrogen (Figure 1-1).  These therapies include the antiestrogen tamoxifen 
(Nolvadex®), which competes with estrogen for binding to the ERα, and aromatase 
inhibitors (anastrazole [Arimidex®], exemestane [Aromasin®], and letrozole [Femara®]), 
which prevent the synthesis of estrogen (4, 5).  However, many tumors develop resistance to 
these antiestrogen therapies (4-6).  ERα-negative breast cancers tend to be more aggressive 
and metastatic than ERα-positive tumors and therapeutic options for many of these patients 
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are much more limited (7).  A subset of ERα-positive and ERα-negative breast cancers 
overexpress the human epidermal growth factor receptor 2 (HER2/ErbB2/Neu), and while 
the advent of HER2 inhibitors, including the HER2 monoclonal antibody trastuzumab 
(Herceptin®) and the dual epidermal growth factor receptor (EGFR/HER1/ErbB1)-HER2 
kinase inhibitor lapatinib (Tykerb®), have improved the survival of some of these patients, 
again the development of resistance to this targeted therapy is a major problem (8-11).  While 
a number of other targeted therapies are in clinical trials either alone or in combination with 
anti-estrogen or HER2 therapies, none has proven to be the “magic bullet” that selectively 
targets the breast cancer cell.  Therefore, new targeted therapies that block other molecules 
driving breast tumor growth are required for breast cancer treatment.   
 
Estrogen signaling in breast cancer.  Estrogen stimulates breast cancer growth via 
genomic and non-genomic signaling mechanisms.  Canonical, “genomic” estrogen signaling 
involves binding of 17β-estradiol (E2) to nuclear ERα, causing a conformational change in 
the ERα.  The ERα then dimerizes and acts as a transcription factor by binding directly to 
DNA via estrogen response elements (EREs), recruiting coactivators, and activating 
transcription (Figure 1-1).  It is now appreciated that estrogen can also induce rapid, non-
genomic signaling.  This signaling is initiated by E2 binding to the ERα in the cytoplasm or 
plasma membrane.  Ligand-associated ERα can interact with various signaling proteins, 
including the EGFR tyrosine kinase, insulin-like growth factor receptor (IGF1R) tyrosine 
kinase, and c-Src tyrosine kinase, leading to downstream activation of signaling through 
ERK mitogen-activated protein kinase (MAPK; a serine/threonine kinase) and AKT 
serine/threonine kinases (Figure 1-1) [reviewed in (4, 6, 12, 13)].  In turn, ERK, AKT, and 
3
p70 S6 kinase (S6K) phosphorylate ERα, enhancing its transcriptional activity (14-17).  
Membrane-bound ERα can also associate with the p85 regulatory subunit of the 
phosphatidyl-inositol-3-OH kinase (PI3K), a lipid kinase that promotes formation of 
phosphotidylinositol 3,4,5-phosphate (PIP3), which then facilitates AKT activation (18).  
These signaling events occur within minutes and also stimulate cell proliferation.  Non-
genomic estrogen signaling is not suppressed by tamoxifen and may contribute to tamoxifen 
resistance (4, 6, 19, 20).  Hence, components of non-genomic estrogen signaling pathways 
may serve as targets for anti-cancer drug discovery. 
 
The Ras family of small GTPases.  Members of the Ras branch (36 genes encoding 
39 proteins) of the Ras superfamily of small GTPases (156 members) regulate a multitude of 
cellular processes, including cell adhesion, differentiation, survival, and proliferation (21) 
(Figure 1-2).  The three Ras isoforms (H-, K-, and N-Ras; the KRAS gene encodes two highly 
identical proteins that differ at their C-terminal sequences due to alternative exon 4 
utilization, termed K-Ras4A and K-Ras4B) relay extracellular stimulus-mediated cell surface 
signals to the cytoplasm and the nucleus (Figure 1-3).  Ras proteins cycle between a GTP-
bound active state and an inactive, GDP-bound conformation.  Ras-specific guanine 
nucleotide exchange factors (RasGEFs; e.g., Sos, RasGRF, RasGRP) promote the exchange 
of GDP for GTP and thereby promote formation of activated Ras-GTP, whereas GTPase 
activating proteins (RasGAPs; e.g., NF1/neurofibromin) negatively regulate Ras GTPases by 
catalyzing the hydrolysis of bound GTP to GDP, thereby forming the inactive Ras-GDP.  The 
conformation of Ras differs in these two nucleotide-bound states in amino acid residues 
referred to as switch 1 (30-38) and switch 2 (60-76) (22).  When bound to GTP, Ras proteins 
4
ARHI
Di-Ras1
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NKIRas1
NKIRas2
RasD1
RasD2
RasL10ARasL10B
RasL11ARasL11B
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Rerg
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K-Ras
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M-Ras
R-Ras
TC21
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Rap1B
Rap2BRap2A
Rap2C Rheb1
Rheb2
Figure 1-2. The Ras branch of the human Ras superfamily of small GTPases. ClustalX was 
used to generate a dendrogram of the GTP-binding domains of human Ras subfamily members. 
The K-Ras2B isoform of K-Ras was used.  Bubbles indicate proteins with established or putative 
roles in breast cancer, discussed in the text.  Pink indicates proteins that suppress breast cancer 
growth (tumor suppressors), whereas green indicates proteins that promote tumor growth.  While 
Rad (yellow) has also been implicated in breast cancer, whether it promotes or suppresses tumor 
growth is unclear.  Adapted from Hanker and Der, Handbook of Cell Signaling, in press.
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Extracellular stimuli
(eg, growth factors)
RTKs*
Effectors*
Off Ras
GAPs*
On
GTP GDP
Pi
GEFs
Ras*
GDP GTP
Raf
Gene expression, cell cycle 
progression, differentiation, 
apoptosis, actin cytoskeletal
remodeling, etc.
Other signals
PI3K RalGEF RASSF1A RIN1
Figure 1-3. Ras signal transduction. Ras GTPases cycle between a GTP-bound “on” state and 
a GDP-bound “off” state.  Ras proteins are positively regulated by GEFs and negatively regulated 
by GAPs.  Ras is activated by growth-factor-stimulated receptor tyrosine kinases (RTKs), such as 
EGFR and HER2.  When bound to GTP, Ras interacts with a variety of downstream effectors to 
control cellular processes.  Asterisks denote proteins that are aberrantly expressed or mutated in 
breast cancer.  The RTKs EGFR and HER2 are frequently overexpressed in breast cancer and 
loss of the RasGAP NF1 leads to an increased risk of breast cancer.  While Ras itself is 
infrequently mutated in breast cancer, mutations in some of its effectors, such as PI3K (PIK3CA), 
are more common.  In addition, loss of the Ras effector RIN1 has been observed in breast cancer.  
Adapted from Hanker and Der, Handbook of Cell Signaling, in press.
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preferentially bind and regulate multiple, functionally distinct effectors (e.g., the Raf 
serine/threonine kinases) to initiate downstream cytoplasmic signaling networks that induce a 
plethora of cellular responses.   
The domain organization of Ras family GTPases is summarized in Figure 1-4A.  The 
amino acids G12 and Q61 of Ras are conserved in the majority of Ras superfamily proteins 
and are essential for intrinsic and GAP-stimulated GTP hydrolysis.  Missense mutations of 
these residues are found in 33% of human cancers 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) (23).  These mutations render Ras 
insensitive to GAPs and thus constitutively GTP-bound and active.  Ras-GTP preferentially 
binds to and activates its downstream effectors via its core effector domain (residues 32-40) 
and flanking switch 1 and 2 sequences.  Although this core effector binding domain is 
conserved in Ras family members, many members of this family signal through distinct 
effectors.  Finally, most Ras family members terminate in a CAAX (C = cysteine, A = 
aliphatic amino acid, X = terminal amino acid) tetrapeptide sequence, a substrate for C15 
farnesyl or C20 geranylgeranyl lipid modification responsible for membrane localization and 
critical for Ras biological activity (Figure 1-5) (24).   
 
Ras posttranslational processing and localization.  Proper subcellular localization 
is critical for activation and effector binding of many small GTPases.  In order for Ras to 
function properly, it must be targeted to the plasma membrane.  This localization is 
accomplished via posttranslational addition of a farnesyl isoprenoid lipid to the C-terminus of 
Ras by the enzyme farnesyltransferase (FTase) (24).  Next, Ras undergoes two additional 
CAAX-signaled post-prenylation modifications (Figure 1-5).  The Ras converting enzyme 1 
7
G12   YDPTIEDSY   Q61                 CVLSH-Ras
Rheb
ARHI
Rerg
R15   YDPTIENTF Q64                 CSVM
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189
GTP
Hydrolysis
Effector
Binding
GTP
Hydrolysis
HV
Domain
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1
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1991
Figure 1-4A. Domain organization of Ras family proteins. ARHI contains a 35-residue N-
terminal extension (N-extension) that may be important for its tumor suppressor activity.  The 
amino acid residues G12 and Q61 in Ras are important for GAP stimulation of GTP hydrolysis; 
mutation of these residues in cancer leads to GAP insensitivity and therefore Ras is constitutively 
GTP-bound and active.  Since these residues are not conserved in ARHI, ARHI may be 
constitutively GTP-bound.  Rheb is regulated by the GAP TSC2, but whether the glutamine at 
position 64 is required for this regulation is unclear.  Whether Rerg is regulated by GAPs is not 
known.  Ras residues 32-40 comprise the core sequences important for effector binding.  Although 
this core effector sequence is conserved between most Ras subfamily members, many Ras-
related GTPases, such as Rheb, use distinct effectors.  The residues in Rheb, ARHI, and Rerg that 
are not conserved in Ras are shown in bold.  The hypervariable (HV) domain in Ras dictates 
subcellular localization, as does the C-terminal CAAX box, required for lipid modification and 
membrane targeting.  Ras, Rheb and ARHI are farnesylated.  Rerg is not farnesylated and does 
not localize to the membrane.  Adapted from Hanker and Der, Handbook of Cell Signaling, in 
press.
A.
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Figure 1-4B. Clustal W was used to generate a complete sequence alignment of H-Ras, Rerg, 
Rheb1, and Rheb2.  The core effector domain is highlighted in yellow.  The CAAX tetrapeptide
motif of H-Ras, Rheb1, and Rheb2 is shown in red.  Rerg lacks a CAAX motif.
B.
H-Ras: M---TEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILD 
Rerg:  MAKSAEVKLAIFGRAGVGKSALVVRFLTKRFIWEYDPTLESTYRHQATIDDEVVSMEILD 
Rheb1: MPQSKSRKIAILGYRSVGKSSLTIQFVEGQFVDSYDPTIENTFTKLITVNGQEYHLQLVD 
Rheb2: MPLVRYRKVVILGYRCVGKTSLAHQFVEGEFSEGYDPTVENTYSKIVTLGKDEFHLHLVD 
   *      *:.:.*   ***::*. :::  .*   ****:*.:: :  .:. :   :.::* 
 
   TAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNK 
   TAGQED-TIQREGHMRWGEGFVLVYDITDRGSFEEVLPLKNILDEIKKPKNVTLILVGNK 
   TAGQDEYSIFPQTYSIDINGYILVYSVTSIKSFEVIKVIHGKLLDMVGKVQIPIMLVGNK 
   TAGQDEYSILPYSFIIGVHGYVLVYSVTSLHSFQVIESLYQKLHEGHGKTRVPVVLVGNK 
   ****:: :     .    .*:: *: :..  **: :      :        :.::***** 
 
   CDLA-ARTVESRQAQDLARSYGIPYIETSAKTRQG-VEDAFYTLVREIR-----QHKLRK 
   ADLDHSRQVSTEEGEKLATELACAFYECSACTGEGNITEIFYELCREVRRRRMVQGKTRR 
   KDLHMERVISYEEGKALAESWNAAFLESSAKENQ-TAVDVFRRIILEAE---------KM 
   ADLSPEREVQAVEGKKLAESWGATFMESSARENQ-LTQGIFTKVIQEIA---------RV 
     **   * :.  :.: ** .   .: * **   :      *  :  *           :  
 
   LNPPDES-GPGCMSCKCVLS 
   RSSTTHVKQAINKMLTKISS 
   DGAASQGKSS------CSVM 
   ENSYGQERR-------CHLM 
    ..  .               
* - single, fully conserved residue
: - conservation of strong groups
. - conservation of weak groups
- no consensus 
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(Rce1) endoprotease cleaves the AAX residues and isoprenylcysteine methyltransferase 
(Icmt) then methylates the C-terminal farnesylated cysteine residue (25, 26).  These 
modifications increase the hydrophobicity of Ras proteins and thus promote association with 
lipids in the membrane.  While farnesylation and post-prenyl processing are necessary for 
proper Ras localization, they are not sufficient (24, 27).  Rather, Ras requires a “second 
signal” to reach the plasma membrane.  For H-Ras and N-Ras, this second signal consists of 
two palmitoylated cysteines in the C-terminal hypervariable domain upstream of the CAAX 
motif.  The second signal of K-Ras4B consists of polybasic residues that facilitate interaction 
with negatively charged phospholipids in the plasma membrane.  Ras proteins that lack these 
second targeting elements show greatly impaired plasma membrane association and 
transforming activities.  As discussed below, inhibition of Ras posttranslational processing 
and membrane association represents an attractive therapeutic strategy to disrupt aberrant 
Ras activity in cancer. 
 
Ras is an oncoprotein.  Ras itself is an oncoprotein and is mutationally activated in 
33% of all cancers, with the highest frequency seen in pancreatic (90%), colorectal (50%) 
and lung (30%) cancers (23, 28).  Extensive studies have implicated Ras in numerous aspects 
of tumor formation and progression (23).  However, Ras is only mutated in 5% of breast 
cancers.  Despite the fact that Ras is rarely mutated in breast cancer, Ras is activated in many 
breast cancers by various upstream regulators, including the epidermal growth factor receptor 
family, in particular EGFR/HER1/ErbB1 and HER2/ErbB2/Neu (29, 30).  Therefore, 
blocking Ras signaling in breast cancer may be therapeutically beneficial.   
10
-CAAX
Ras -CAAX
FTase
Ras -C
Ras -C-OMe
Rce1
Icmt
Plasma Membrane
Cytoplasm
Ras
FTI 
=
Farnesyl Isoprenoid Lipid
CAAX = Cys-Aliphatic-Aliphatic-Ser/Met
Cytosolic,
inactive
Membrane-associated,
active
Figure 1-5. Ras posttranslational processing and membrane association. Most members of 
the Ras subfamily, including Ras, Rheb, and ARHI/Noey2, are processed by a series of 
posttranslational modifications that allow insertion into the plasma membrane or endomembranes.  
The first step in this process is the addition of a farnesyl isoprenoid lipid to the cysteine residue of 
the CAAX motif by FTase; FTIs block this step.  Next, the endonuclease Rce1 cleaves the –AAX 
tripeptide and the methyltransferase Icmt methylates the now terminal farnesylated cysteine (O-
Me).  Complete processing is required for proper Ras localization and function.  While FTIs have 
shown promise in breast cancer clinical trials, they do not inhibit K-Ras4B prenylation, and the 
FTase substrates responsible FTI inhibition of breast cancer growth are not known. Adapted from 
Hanker and Der, Handbook of Cell Signaling, in press.
FTS
TLN-4601 
Cysmethynil
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Recently, several Ras family proteins have been implicated in breast cancer and may 
play significant roles in the initiation and progression of this disease.  These proteins include 
Rheb (Ras homolog enriched in brain), an activator of the mTOR signaling pathway involved 
in estrogen-regulated breast cancer, and Rerg (Ras-related estrogen-regulated growth 
inhibitor) and ARHI (Ras homologue member I, also known as Di-Ras3 or Noey2), two Ras 
family proteins that, in contrast to Ras and Rheb, negatively regulate breast cancer growth 
and may function as tumor suppressors rather than oncogenes (Figure 1-2).  Here, I focus on 
these Ras family proteins and their involvement in breast cancer.  In particular, my thesis has 
explored the roles of two of these small GTPases, Rerg and Rheb, in breast cancer 
progression, with an emphasis on therapeutic strategies to reverse aberrant Rerg or Rheb 
activity in cancer. 
 
Ras in breast cancer.  Ectopic expression of mutationally activated Ras is capable of 
transforming immortalized human mammary epithelial cells and transgenic Ras expression 
drives mammary tumor development in mice (31).  Furthermore, ectopic expression of Ras in 
the estrogen-dependent MCF-7 cell line promotes estrogen-independent growth (32-34).  
However, evidence for activation of endogenous Ras in human breast tumors is more limited.  
The growth factor receptors EGFR and HER2 are aberrantly activated by overexpression in 
breast cancers and can cause upstream activation of Ras (Figure 1-1). Studies have found that 
the levels of activated, GTP-bound Ras are increased in breast tumors and cell lines 
overexpressing EGFR or HER2 (29, 30).  Therefore, Ras may be activated in breast tumors 
in the absence of direct mutational activation of Ras.  Ras proteins are also overexpressed in 
20-50% of breast cancers.  Another mechanism by which Ras may be activated in breast 
12
cancer could be decreased expression of a negative regulator of Ras, such as a RasGAP.  
Women with the genetic disease neurofibromatosis, caused by inactivating mutations of the 
NF1 gene, which encodes the neurofibromin RasGAP, have an increased risk of developing 
breast cancer (35, 36), but whether the NF1 tumor suppressor is downregulated in 
spontaneous breast cancers is not known.   
Recent work by Song and colleagues has revealed a mechanism by which H-Ras 
expression is elevated in breast tumor-initiating cells, which may represent breast cancer 
“stem cells” (37).  They showed that expression of the microRNA let-7, a negative regulator 
of H-Ras protein expression, is reduced in breast tumor-initiating cells (cancer stem cells) 
and in clinical samples.  They further showed that restoring let-7 expression reduced H-Ras 
expression, cell proliferation, mammosphere formation, tumorigenicity, and metastasis, and 
that silencing H-Ras alone was sufficient to reduce mammosphere formation, tumor 
formation, and metastasis (37).  Thus, H-Ras inhibition may represent a promising 
therapeutic approach for targeting breast cancer stem cells.  Further work is needed to 
determine whether H-Ras levels are increased in independently-derived populations of breast 
cancer stem cells. 
 GTP-bound Ras associates with a variety of effectors to elicit a diverse array of 
cellular responses.  The best characterized Ras effectors implicated in oncogenesis include 
the Raf serine/threonine kinases, the PI3Ks, and GEFs for the Ral GTPases (RalGEFs) (38).  
Mutations in the genes encoding B-Raf and the p110α catalytic subunit of PI3K (PIK3CA) 
have been identified in many cancers, supporting a role for these Ras effectors in 
oncogenesis.  While BRAF mutations are rare in breast cancer, PIK3CA is mutated in 20-40% 
of human breast cancers (39) and its occurrence is mutually exclusive with Ras mutations in 
13
breast cancer cell lines (40).  However, Ras also activates some effectors that negatively 
regulate cancer growth; silencing of these effectors, such as the RASSF1 tumor suppressor 
and its family members, is a common event in cancer (41, 42).  Hypermethylation of the 
RASSF1A promoter has been observed in 80-90% of breast cancers (43, 44), but a definitive 
role for RASSF1A in breast cancer has not yet been established.  The Ras effector RIN1 was 
recently implicated as a tumor suppressor in breast cancer.  RIN1 regulates epithelial cell 
properties such as cytoskeletal remodeling through Abl tyrosine kinases (45).  Colicelli and 
colleagues found that RIN1 levels are reduced in primary breast tumors and in breast cancer 
cell lines, and that restoring RIN1 expression suppressed tumor growth (46).  Whether loss of 
RIN1 correlates with Ras activation, and whether its loss is necessary for Ras-induced tumor 
growth, is not known. 
  
Therapeutic targeting of Ras.  Due to the unequivocal importance of Ras in human 
cancer development and progression, there have been considerable efforts to develop 
pharmacologic agents that block Ras function for cancer therapy.  One major approach has 
been the development of inhibitors of effector signaling, in particular inhibitors of the Raf-
MEK-ERK and PI3K-AKT-mTOR pathways (Figure 1-6) (47, 48), although combining 
inhibitors of these two pathways may be required for the treatment of tumors bearing Ras 
mutations (49).  A second major focus has been inhibition of Ras membrane association 
(Figure 1-5 and 1-6).  FTase inhibitors (FTIs) were originally developed to block Ras 
localization and thereby block Ras function in cancer.  However, it is now appreciated that 
FTIs do not in fact block localization of the most commonly mutated Ras isoforms in cancer, 
K-Ras4B and N-Ras.  These Ras isoforms escape FTI inhibition by a process known as 
14
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alternative prenylation, whereby they are modified by addition of another isoprenoid lipid, 
geranylgeranol; geranylgeranylated Ras proteins remain functional and transforming in the 
presence of FTIs (50).  Despite an inability to effectively block Ras, FTIs have shown some 
anti-tumor activity, particularly in breast cancer (51).  Since other substrates of FTase do 
have known roles in cell proliferation (e.g., Rheb) (52), the anti-tumor activity of FTIs may 
be due to inhibiting the function of these proteins.  FTIs have also demonstrated clinical 
activity in combination with hormonal therapies in breast cancer (53, 54).  Elucidating the 
FTase substrates responsible for the anti-tumor activity of FTIs in breast cancer could be very 
beneficial in selecting patients that may respond to this targeted therapy. 
 Due to the failure of FTIs to successfully block K- and N-Ras activity, attention has 
turned to other methods of disrupting Ras membrane association.  Initial studies suggested 
that blocking Rce1- or Icmt-mediated modifications may not impair Ras transforming 
activity, since Ras mutants that were not modified by Rce1 or Icmt lost only 50% of their 
membrane localization and transforming activity (55).  More recent studies using genetic 
ablation of Rce1 and Icmt have suggested that inhibition of these enzymes may indeed block 
Ras-induced oncogenesis.  For example, mice lacking Icmt displayed reduced lung tumor 
formation and reduced myeloproliferation phenotypes driven by mutant KRAS (56), but 
whether this was directly due to Ras inhibition is not known.  Although Rce1 deficiency 
reduced Ras membrane association and transformation (57), Rce1 deficiency actually 
accelerated Ras-induced myoproliferative disease in mice (58), perhaps because Rce1 is 
required for proteolytic processing of many other CAAX-terminating proteins besides Ras.  
Whether Rce1 deficiency blocks the growth of other Ras-dependent tumors is not known.  
16
Therefore, recent efforts have focused on developing pharmacological inhibitors of Icmt to 
block Ras-driven cancer. 
 Several inhibitors of Icmt have been reported, including S-adenosylhomocysteine 
(AdoHcy), which inhibits many methyltransferases, and prenylcysteine analogs such as N-
acetyl-S-farnesyl-L-cysteine (AFC) (25, 26).  However, these compounds lack specificity and 
have considerable off-target effects unrelated to Icmt inhibition (26).  More recently, Casey 
and colleagues used a chemical library screen to identify a small molecule inhibitor of Icmt, 
cysmethynil (59).  Cysmethynil was shown to mislocalize Ras, block the anchorage-
independent growth of colon cancer cells in an Icmt-dependent fashion, and reduce tumor 
xenograft growth of PC3 prostate cancer cells (59, 60).  Cysmethynil was also shown to 
induce autophagy and disrupt mTOR signaling (60).  Whether the anti-tumor effects of 
cysmethynil are due specifically to Ras inhibition is not known. 
Farnesyl isoprenoid-containing small molecules represent another pharmacological 
approach to interfere with Ras membrane localization and function (Figure 1-6 and 1-7).  
Because these compounds contain a farnesylated isprenoid, they are proposed to compete 
with farnesylated Ras for membrane-associated Ras binding partners (e.g., galectins) and 
dislodge Ras from the membrane, thereby antagonizing Ras signaling and function (61).  
There are currently two such molecules undergoing clinical evaluation: FTS (salirasib) and 
TLN-4601.  FTS has been shown to dislodge Ras from the membrane, prevent Ras from 
binding to galectin-1 in the membrane, promote degradation of Ras protein, decrease levels 
of Ras-GTP, and inhibit Ras activation of the Raf-MEK-ERK pathway (62-64).  In addition, 
FTS reversed Ras-induced transformation, but not transformation driven by Raf (65, 66), 
indicating selectivity for Ras-transformed cells.  Furthermore, FTS inhibited the growth of 
17
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many human cancer cell lines in vitro and in vivo (67-74), prompting clinical investigation.  
FTS is currently in Phase I/II clinical trials (www.clinicaltrials.gov) and is well tolerated 
(75).  The results of a recent phase II trial of FTS in combination with gemcitabine for the 
treatment of pancreatic cancer are particularly encouraging.  The combination resulted in a 
median survival period of greater than 10.8 months and a one-year survival rate of 50% (76).  
Importantly, tumor biopsies showed that FTS treatment reduced the levels of Ras protein 
(76).  Interestingly, FTS has also been shown to inhibit the growth of breast cancer cells and 
block mTOR signaling (77-79).  Whether the anti-tumor effects of FTS are due to Ras 
inhibition or inhibition of the mTOR pathway is not known.  More potent FTS derivatives are 
currently being developed (80). 
Another farnesyl-containing small molecule is TLN-4601 (formerly ECO-4601), a 
farnesylated dibenzodiazepinone natural product isolated from Micromonospora bacteria 
(81).  In addition to being a farnesylcysteine mimetic like FTS (Figure 1-7), TLN-4601 also 
binds selectively to the peripheral benzodiazepine receptor (PBR) (81).  The PBR is 
overexpressed in some tumors and may promote the preferential uptake of TLN-4601 in 
tumors (82).  Micromolar concentrations of TLN-4601 have broad cytotoxic activity.  TLN-
4601 was also shown to have significant antitumor activity in xenografts of several human 
cell lines that overexpress the PBR (81).  A phase I/II clinical trial found that TLN-4601 is 
safe and well-tolerated in patients.  TLN-4601 is now in a phase II clinical trial as a second 
line therapy for glioblastoma multiforme (www.clinicaltrials.gov).  Whether, like FTS, TLN-
4601 also inhibits Ras activity has not been thoroughly evaluated. 
 
19
Rheb.  Rheb1 and Rheb2 (51% amino acid identity; Figure 1-4B) are members of the 
Ras family of small GTPases (83) that may have increased activity in breast cancer.  Rheb is 
a critical component of the AKT-TSC-mTOR pathway which responds to a plethora of 
cellular signals to regulate protein translation, cell size, and cell cycle progression (Figure 1-
8) (84).  The tumor suppressor TSC2 (tuberin), in complex with TSC1 (hamartin), functions 
as a GAP towards Rheb and thereby suppresses Rheb-GTP formation and signaling (85, 86).  
The role of TSC2 in Rheb signaling is analogous to that of the RasGAP NF1—loss of NF1 in 
neurofibromatosis type I leads to hyperactivation of Ras. Similarly, loss-of-function 
mutations in the TSC1 or TSC2 genes cause the Mendelian disorder tuberous sclerosis, which 
is characterized by the formation of benign hamartomas in a variety of organs (87, 88).  In 
this disease, loss of TSC2 or TSC1 results in hyperactivation of Rheb and promotes Rheb-
mediated activation of the mTOR (mammalian Target of Rapamycin) complex 1 (mTORC1), 
which consists of mTOR, raptor, and GβL (mLST8).    Rheb does not activate a second 
mTOR complex, mTORC2 (consisting of mTOR, rictor, GβL, and Sin1), which is regulated 
by other mechanisms (89).  Although Rheb binds to mTOR irrespective of GDP or GTP 
association, Rheb activates mTOR only when bound to GTP (90).  The mechanism by which 
Rheb-GTP activates mTOR is incompletely understood, but may involve association with 
FKBP38 and phospholipase D1 (PLD1).  Sun et al. recently showed that Rheb binds and 
activates PLD1 in a GTP-specific manner and that PLD1 is required for Rheb activation of 
the mTOR pathway (91).  Bai et al. suggested that FKBP38 negatively regulates mTORC1 
signaling, and that Rheb-GTP association with FKBP38 relieves this negative regulation, 
leading to mTORC1 activation (92-94).  However, this model has recently been challenged 
by multiple studies (95-97).   
20
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Rheb activation of mTOR may also involve enhanced recruitment of the mTORC1 
substrates eIF4E binding protein 1 (4E-BP1) and p70 S6 kinase (S6K) (93, 96).  mTOR-
mediated phosphorylation of these two substrates promotes protein translation (Figure 1-9).  
Hypophosphorylated 4E-BP1 binds and sequesters the translation initiation factor eIF4E.  
Phosphorylation of 4E-BP1 by mTOR allows the release if eIF4E, which promotes cap-
dependent mRNA translation and tumorigenesis (98).  S6K phosphorylates the S6 ribosome 
subunit, also promoting increased protein translation, ribosome biogenesis, and the 
development of benign tumors. 
Recent studies have found that Rheb can be regulated independently of TSC2 and that 
Rheb also exhibits mTOR-independent functions (Figure 1-8).  Although the Translationally 
Controlled Tumor Protein (TCTP) was reported originally to be a GEF for Rheb in 
Drosophila melanogaster (99), subsequent studies have failed to confirm it as a GEF for 
mammalian Rheb (95, 100).  Thus, a bona fide GEF for Rheb in mammalian cells has yet to 
be identified.  Several proteins have been shown to negatively regulate Rheb by binding and 
sequestering it away from mTOR.  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
binds directly to Rheb and inhibits Rheb/mTOR signaling under low glucose conditions 
(101).  The hypoxia-inducible protein Bnip3 binds Rheb and blocks Rheb-induced mTOR 
activation during hypoxia (102).  Rheb-mTOR signaling is also regulated by amino acid 
availability independently of TSC2.  The Rag GTPases have been suggested to mediate 
amino acid-induced mTOR activation by promoting subcellular localization of mTOR to a 
compartment containing Rheb (103-105).  RalGDS and RalA have also been shown to 
promote Rheb activation of mTOR in response to amino acids (106).  This tight regulation of 
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Figure 1-9. Estrogen regulation of Rheb signaling. When bound to estrogen (E2), the ERα
can initiate rapid, “non-genomic” signaling through PI3K.  PI3K is a lipid kinase that converts PIP2 
into PIP3.  The reverse reaction is catalyzed by the lipid phosphatase PTEN, a negative regulator 
of the pathway.  PIP3 leads to activation of Akt, which then phosphorylates a variety of substrates 
involved in cell proliferation and survival, including TSC2.  Akt-mediated phosphorylation of TSC2 
inactivates its RhebGAP activity, leading to increased levels of Rheb-GTP.  The mechanism by 
which Rheb activates mTOR is not entirely understood, but may involve displacement of the 
mTOR inhibitor FKBP38 and/or activation of PLD1.  The mTORC1 complex (mTOR, raptor, and 
mLST8) phosphorylates substrates involved in protein translation, including S6K and 4E-BP1.  
S6K can also phosphorylate the ERα, stimulating its transcriptional activity.  Rheb is inhibited by 
FTIs and mTOR is inhibited by rapamycin.  Green indicates positive regulators of the pathway; red 
indicates negative regulators.  Asterisks denote proteins that are known to be mutated or 
aberrantly expressed in breast cancer. Adapted from Hanker and Der, Handbook of Cell 
Signaling, in press.
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Rheb and mTOR activation ensures that the cell will not waste energy and nutrients by 
engaging in protein synthesis under suboptimal conditions. 
Although mTOR is the best studied Rheb effector, Rheb has been shown to possess 
mTOR-independent functions (Figure 1-8).  Multiple studies have found that Rheb binds to 
Raf-1 and B-Raf and inhibits their activity (107-111).  Whether tumors containing 
hyperactive Rheb exhibit reduced Raf activity is not known.  Rheb has recently been shown 
to inhibit dynein-dependent transport of misfolded proteins and thereby block aggresome 
formation (112).  The direct effector of Rheb responsible for this process has not yet been 
identified.  While mTOR has been shown to be the primary Rheb effector involved in 
tumorigenesis (113, 114), whether these mTOR-independent Rheb functions also contribute 
to tumor formation, or perhaps restrict tumor growth in tuberous sclerosis patients, is not 
known. 
Recent studies have strengthened the case for the involvement of Rheb in sporadic 
tumor development (Figure 1-10).  Rheb1 and Rheb2 are overexpressed in a variety of 
tumors, including breast, prostate, lung, colon, ovary, glioma, and oral squamous cell 
carcinoma (114-118).  In addition, a Rheb mutation has been found in colon cancer (119), 
and the RHEB gene is amplified in some prostate cancers (118).  Furthermore, an activated 
Rheb mutant was found to transform chick embryo fibroblasts (114) and Rheb 
overexpression promoted tumor formation in mouse models of lymphoma and prostate 
cancer (113, 118).  Others have found that Rheb is involved in the survival of dormant tumor 
cells (120) and in resistance to chemotherapeutics (113, 115).  Therefore, it is likely that 
Rheb inhibition will be therapeutically beneficial both for the treatment of TSC and for a 
variety of cancers, including breast cancer. 
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 Although mutations of TSC1 and TSC2 are not found in breast cancer, other 
mechanisms may activate Rheb in breast cancer.  Studies have found reduced expression of 
TSC1 and TSC2 in breast cancer (121).  The mRNA levels of both Rheb1 and Rheb2 are 
elevated in breast cancer cells (115).  The TSC2-Rheb-mTOR pathway can also be activated 
by genetic alterations that cause activation of PI3K and its target, the serine-threonine kinase 
AKT (Figure 1-9).  PI3K promotes formation of PIP3, which facilitates AKT membrane 
association and activation.  AKT phosphorylates and inactivates TSC2, leading to an increase 
in GTP-bound Rheb.  The PI3K-AKT pathway is one of the most commonly activated 
pathways in breast cancer (39).  In particular, mutational activation of the gene encoding 
p110α, the catalytic subunit of PI3K, is is one of the most frequent gene mutations found in 
breast cancer (119).  Loss of the PTEN tumor suppressor, a negative regulator of PI3K, is 
alos prevalent in breast cancer (122).   PTEN encodes a lipid phosphatase that converts PIP3 
back to PIP2. 
Like Ras, Rheb can be hyperactivated in breast cancer by upstream signals.  HER2 
and EGFR overexpression can cause activation of PI3K and thus Rheb (Figure 1-8).  Other 
growth factor-regulated kinases, such as ERK and RSK, also phosphorylate and inactivate 
TSC2, thereby promoting Rheb-GTP formation (Figure 1-8) (123, 124).  Furthermore, 
estrogen can trigger Rheb signaling in the MCF-7 ERα-positive breast cancer cell line.  
Estrogen activates PI3K and AKT through non-genomic mechanisms (Figure 1-9) and 
estrogen treatment was recently found to increase Rheb-GTP levels and to stimulate 
downstream signaling through mTOR (125, 126).  Rheb was also shown to be required for 
estrogen-induced DNA synthesis and cell cycle progression in MCF-7 cells (126).  In 
addition, mTOR is required for estrogen-induced MCF-7 cell proliferation (127).  Rheb and 
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mTOR have also been implicated in tamoxifen resistance: Rheb inhibition increased 
sensitivity to tamoxifen (115) and mTOR inhibition prevented AKT-induced tamoxifen 
resistance in MCF-7 cells (128, 129).   Therefore, inhibiting Rheb signaling may be 
beneficial in ERα-positive and tamoxifen-resistant breast cancers.  Further research is needed 
to determine the role of Rheb in tamoxifen resistance and to validate Rheb as a therapeutic 
target for the treatment of breast cancer. 
 
Inhibitors of the Rheb-mTOR pathway in breast cancer.  Like Ras, Rheb 
terminates in a CAAX motif and is farnesylated.  Farnesylation is essential for its proper 
localization and function (86, 107, 114, 115, 130-132).  FTIs block Rheb signaling and 
function and unlike Ras, Rheb does not undergo FTI-induced alternative prenylation (107, 
115, 131).  Therefore, Rheb inhibition may be partially responsible for the anti-breast cancer 
effects of FTIs.  Basso et al. showed that the FTI lonafarnib (Sarasar®) enhanced tamoxifen-
induced apoptosis, and this enhancement was prevented by a lab-generated FTI-resistant, 
geranylgeranylated mutant of Rheb (GG-Rheb) (115).  GG-Rheb was also shown to rescue 
the anti-tumor effects of FTIs in lymphoma cells (113).  Determining whether this FTI-
resistant GG-Rheb variant prevents FTIs from decreasing breast cancer growth may validate 
Rheb activation status as a biomarker for the selection of patients who may benefit from FTI 
therapy.  My studies in Chapter 3 focus on blocking CAAX-mediated posttranslational 
processing as a means to inhibit Rheb-mTOR signaling in breast and other cancers. 
FTIs are currently in clinical trials and have showed promise for the treatment of 
advanced breast cancers.  Preclinical studies have shown synergistic activity when FTIs were 
given in combination with tamoxifen (53, 133).  In a phase II clinical trial, 24% of patients 
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with hormone-refractory breast cancers showed clinical benefit when treated with the FTI 
tipifarnib (Zarnestra®) (54).  Tipifarnib has shown promising results in a phase II trial in 
combination with tamoxifen, achieving stable disease in 55% of patients (53).  In contrast, a 
phase II study found that the addition of tipifarnib to letrozole did not improve the objective 
response rate (134), suggesting that tipifarnib may not be beneficial in combination with 
aromatase inhibitors.   
mTOR has been well validated as a target for anti-cancer therapeutics and several 
mTOR inhibitors are currently under clinical evaluation (135, 136).  In addition, the 
rapamycin analogs temsirolimus (Torisel®) and everolimus (Afinitor®) have recently been 
approved for the treatment of advanced renal cell carcinoma (136).  Rapamycin analogs have 
also shown promise in combination with either endocrine therapies or HER2 inhibitors in 
clinical trials for breast cancer (53, 137, 138).  As mentioned above, FTS has also been 
shown to inhibit mTOR (79), and FTS reduced the growth of estrogen-dependent and long-
term estrogen-deprived MCF-7 cells (77, 78, 139).  Therefore, mechanistically distinct 
inhibitors of the Rheb-mTOR pathway may help to overcome the development of resistance 
to current targeted therapies in breast cancer.   
 
ARHI/Di-Ras3/Noey2.  Whereas RAS is an oncogene, and many genes encoding Ras 
subfamily members, such as Rheb, promote growth, there are also several Ras-related genes 
that have been implicated as tumor suppressor genes in breast cancer.  One such gene, ARHI, 
was identified originally by Bast and colleagues by using differential display PCR in ovarian 
cancer cells to identify genes whose expression is lost in tumor cells (140).  ARHI is 
maternally imprinted and expressed monoallelically.   Loss of heterozygosity, in which the 
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non-imprinted allele was deleted, was reported in 41% of breast and ovarian cancers (140).  
ARHI expression is also negatively regulated by promoter hypermethylation, decreased 
mRNA stability, and transcriptional regulation by histone deacetylase (HDAC)-E2F 
complexes (141-143).  ARHI expression was found to be reduced in 70% of invasive breast 
carcinoma tissues and decreased expression was associated with breast cancer progression 
and lymph node metastases (144, 145).  Recently, mutations in ARHI were found in 42% of 
breast cancer tissues as well as 34% of breast hyperplasias (146), suggesting that disruption 
of ARHI is an early event in breast tumorigenesis.  ARHI expression is also downregulated in 
several other cancers, including pancreatic cancer, thyroid cancer, and non-small cell lung 
cancer, suggesting that loss of ARHI may be an important step in oncogenesis (147).   
Ectopic reexpression of the ARHI protein was found to reduce the clonogenic growth 
of breast and ovarian cancer cells, reduce cyclin D1 promoter activity, and increase p21CIP1 
expression (140), supporting a tumor suppressor and cell cycle inhibitory function.  Bast and 
colleagues further showed that ARHI re-expression inhibited breast cancer cell proliferation 
and tumor xenograft formation and induced calpain-dependent apoptosis in breast and 
ovarian cancer cells (148).  Since ARHI is divergent at two key residues important for the 
intrinsic GTPase activity of Ras and Ras-related proteins (residues A46 and G95), ARHI may 
be locked in a constitutively active conformation and may not be regulated by GDP/GTP 
cycling (Figure 1-4A).  The mechanism of ARHI-induced tumor suppression was shown to 
depend on its unique N-terminal extension (149), absent in other Ras family members 
(Figure 1-4A), and to involve inhibition of the signal transducer and activator of transcription 
STAT3 (150).  Strategies to cause reexpression of ARHI may represent an attractive therapy 
for ARHI-negative breast cancer patients. 
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Like Ras and Rheb, ARHI terminates in a CAAX motif, is farnesylated, and does not 
undergo alternatively prenylation.  The farnesylation of ARHI is essential for its membrane 
association and growth inhibitory function (149).  Therefore, it may be an important “off-
target” for FTIs that results in promotion, rather than inhibition, of growth. 
 
Rerg.  Like ARHI, Rerg is another Ras-related small GTPase that is downregulated 
in breast cancers and is thought to play a growth-inhibitory role.  Rerg was initially identified 
in a microarray gene expression screen where its expression was decreased in the most 
aggressive, ERα-negative subtypes (2, 151).  Rerg was found to be a transcriptional target of 
the ERα, which functions as a transcription factor when bound to estrogen (Figure 1-11).  
Rerg expression was stimulated by estrogen treatment and reduced by the anti-estrogen 
tamoxifen (151).  Other microarray studies have found decreased Rerg expression in several 
different types of cancer and in metastatic cancers relative to their non-metastatic 
counterparts (152), suggesting that loss of Rerg expression may play a role in tumor 
progression and metastasis.   
Unlike Ras and Rheb, which are evolutionarily conserved from yeast to humans, Rerg 
has evolved more recently.  Rerg is conserved in mammals, chickens (gallus gallus), 
zebrafish (danio rerio), and frogs (xenopus tropicalis), but is not found in invertebrates or 
outside of the animal kingdom.  While Rerg shares substantial sequence identity with Ras 
(42%), particularly in the core effector domain (Figure 1-4), Rerg does not bind to canonical 
Ras effectors and no Rerg effectors have been identified to date (Figure 1-12).  Rerg was 
shown to bind and hydrolyze GTP (151), but whether GTP binding is required for Rerg 
activity is not known.  Additionally, no GEF(s) or GAP(s) for Rerg have been identified.  
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Figure 1-11. Estrogen regulation of Rerg expression. When bound to estrogen (E2), the ERα
can function as a transcription factor in the nucleus.  The RERG promoter contains an upstream 
estrogen response element (ERE).  When the ERα binds to EREs, it recruits transcriptional 
coactivators to activate transcription of estrogen-responsive genes such as Rerg.  Rerg expression 
correlates with ERα expression in breast cancer; ERα-negative breast cancers lack Rerg
expression.  Adapted from Hanker and Der, Handbook of Cell Signaling, in press.
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Figure 1-12. Unknown mediators of Rerg signal transduction. Like Ras and Rheb, Rerg
cycles between GDP- and GTP-bound states.  Whether Rerg is only “active” when GTP-bound is 
not known.  Furthermore, regulators of Rerg GTPase cycling and upstream signals that promote or 
inhibit Rerg GTP binding have not yet been identified.  Finally, while the Rerg effector domain is 
similar to that of Ras, Rerg does not bind to canonical Ras effectors, and Rerg effectors that 
mediate growth inhibition or other functions of Rerg have yet to be identified.  Adapted from Key et 
al., Methods Enzymol 2005;407:513-27.
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Furthermore, whether Rerg is activated by growth factor signaling, like Ras and Rheb, is not 
known.  Unlike most Ras family members, Rerg lacks the C-terminal CAAX motif and is 
localized primarily in the cytosol (151, 153).  Overexpression of Rerg in MCF-7 cells 
decreased cell proliferation and xenograft formation (151), suggesting that Rerg is a growth 
inhibitor in breast cancer.  However, ectopic reexpression of Rerg in ERα-negative, Rerg-
negative breast cancer cell lines did not affect anchorage-dependent or –independent growth 
or invasion (152), casting doubt on the role of Rerg as a tumor suppressor in breast cancer.  
My studies further evaluating the role of Rerg as a tumor suppressor in breast cancer will be 
presented in Chapter 2.  More studies are needed to confirm the role of Rerg as a growth 
inhibitor in breast cancer in vivo. 
 
Other Ras Family Proteins in Breast Cancer.  There are several other members of 
the Ras subfamily that have been implicated in breast cancer, but more studies are needed to 
validate the importance of these proteins in breast cancer.  Rap1, a Ras-related protein 
involved in integrin and cadherin signaling, was shown to be involved in breast cancer lumen 
formation (154).  Rap1 activity was elevated in a malignant breast cancer cell line compared 
to its nonmalignant counterpart when cultured in three-dimensional laminin-rich extracellular 
matrix (154).  Dominant-negative Rap1, which blocks GEF activation of endogenous Rap1, 
restored tissue polarity and induced lumen formation in breast cancer cells.  Dominant-
negative Rap1 also reduced tumor incidence in mice, whereas constitutively active Rap1 
increased invasiveness and tumorigenicity (154).  Determining whether GTP-bound Rap1 is 
increased in primary breast cancer tissue and whether RNAi-mediated silencing of Rap1 in 
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multiple breast cancer cell lines reduces tumorigenicity and invasion will strengthen the 
evidence for the importance of Rap1 in breast cancer tumorigenesis. 
 Rad (R-Rad/Rem3) is a Ras-related GTPase that is normally expressed in heart, 
skeletal muscle, and lung tissues (155).  Multiple groups have reported reduced expression of 
Rad in breast cancers (156, 157), suggesting a role for Rad as a tumor suppressor.  However, 
ectopic expression of Rad in MDA-MB 435 breast cancer cells was shown to increase 
anchorage-independent growth and tumor formation in mice, implicating Rad as an oncogene 
instead of a tumor suppressor (156).  Coexpression of the metastasis suppressor nm23, which 
interacts with Rad, inhibited Rad-induced breast cancer cell growth (156).  More work is 
needed to resolve whether Rad is a tumor suppressor or an oncogene in breast cancer, and 
whether these discrepancies reflect cell context differences in function. 
 The Ral GTPases (RalA and RalB) have recently garnered attention for their roles in 
promoting oncogenesis, tumor growth, and metastasis (158).  Ral GTPases function 
downstream of the Ras effector, RalGEF, and the RalGEF-Ral pathway is required for Ras-
induced transformation in human cells (159).  However, whether RalA and RalB are 
involved in breast cancer is not known.  Ral was shown to be required for EGFR-induced 
estrogen-independent growth in MCF-7 cells, but constitutively active RalA was not 
sufficient to promote estrogen-independent growth (160).  Missense mutations in the RalGEF 
Rgl1 have been found in breast cancer (161), but whether these mutations activate Ral and 
drive tumorigenesis has not been determined.  Clearly, further research is warranted in order 
to determine whether targeting Ral or Rgl1 would be beneficial in breast cancer. 
 The GEF BCAR3 was found in a screen to identify proteins that promote tamoxifen 
resistance (162).   While BCAR3 overexpression does indeed promote antiestrogen 
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resistance, the question of which downstream GTPase it utilizes to do so is controversial.  
Studies originally implicated the mouse homolog of BCAR3, AND-34, as a GEF for RalA, 
Rap1A, and R-Ras (163).  However, overexpression of AND-34 failed to activate RalA or R-
Ras in breast cancer cells (160, 164), and AND-34-induced antiestrogen resistance was found 
to be mediated by PI3K and Rac1 (164, 165).  Nevertheless, constitutively active R-Ras was 
sufficient to induce estrogen-independent MCF-7 cell proliferation (160).  Future studies to 
address whether R-Ras activity is elevated in tamoxifen-resistant breast cancer tissues will 
help to evaluate its role in breast cancer. 
 In summary, members of the Ras subfamily of small GTPases may represent 
attractive targets for the treatment of breast cancer, but more research is needed to fully 
validate the causal roles of these proteins in breast cancer.  In addition, other small GTPases, 
including members of the Rho and Rab subfamilies, have been implicated in breast cancer 
and have been reviewed elsewhere (166-168).  Unlike protein kinases or cell surface 
receptors, GTPases have not been classically considered promising druggable targets.  The 
successful development of ATP-competitive inhibitors of protein kinases as anti-cancer drugs 
prompted the consideration of similar approaches for blocking Ras family small GTPase 
function.  However, in contrast to the micromolar binding affinity of protein kinases for 
ATP, GTPases bind GTP with picomolar affinities; therefore, small molecule approaches to 
block GTP binding are not feasible.  As strategies to therapeutically inhibit small GTPase 
signaling improve, it will be imperative to understand the contributions of each of these 
proteins to breast cancer development and progression. 
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Rationale for studies.  Several members of the Ras family of small GTPases have 
been implicated in breast cancer and may represent therapeutic targets for the treatment of 
either ERα-positive or ERα-negative breast cancers.  I have chosen to focus on the roles of 
Rerg and Rheb, two estrogen-regulated Ras family small GTPases, in breast cancer.  Rerg is 
regulated by classical, genomic estrogen signaling and is not expressed in ERα-negative 
breast cancers.  ERα-negative breast cancers are the most advanced, poorly differentiated, 
invasive, and fatal types of breast cancer.  There are currently no therapies tailored 
specifically to ERα-negative breast cancers, particularly those that do not overexpress HER2.  
Thus, ERα-negative breast cancers are in dire need of directed therapies that limit their 
invasiveness and malignancy.  Restoring expression of the ERα in ERα-negative breast 
cancer cell lines reduces their invasiveness (169), but the key transcriptional targets of the 
ERα responsible for inhibiting invasion are currently unknown.  I hypothesized that loss of 
Rerg might contribute to the enhaced aggressiveness of ERα-negative breast cancers, since 
Rerg had been implicated as a growth inhibitor in breast cancer.  As discussed above, many 
facets of Rerg signaling are unknown, and thus ripe for discovery.  In particular, I was 
interested in determining whether reducing Rerg expression in ERα-positive breast cancer 
cells might increase growth and invasion, or whether restoring Rerg expression in ERα-
negative breast cancer cells would decrease growth and invasion.  Thus, I created tools to 
manipulate Rerg expression: I used short hairpin RNA (shRNA) targeting Rerg to knock 
down Rerg expression in two ERα-positive breast cancer cell lines and used a tamoxifen-
inducible ER-Rerg fusion protein to restore Rerg expression in two ERα-negative breast 
cancer cell lines.  As discussed in Chapter 2, knocking down or restoring Rerg expression did 
not significantly disrupt the growth or invasive properties of breast cancer cells.  Therefore, 
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more studies are needed to determine the role of Rerg both in normal physiology and in 
cancer development. 
 Rheb is also regulated by estrogen, but in a different manner: rather than being a 
transcriptional target of the ERα, Rheb is activated by non-genomic estrogen signaling in 
breast cancer.  Rheb was also shown to be involved both in breast cancer and in many other 
cancers.  Thus, Rheb represents an attractive therapeutic target for the treatment of breast and 
other cancers.  Chapter 3 of my thesis explores strategies to inhibit Rheb signaling in cancer.  
I hypothesized that inhibitors of CAAX-mediated posttranslational processing would block 
Rheb localization, Rheb activation of mTOR, and, ultimately, Rheb-dependent tumor growth.  
I found that the post-prenylation processing enzymes Rce1 and Icmt were required for proper 
Rheb localization, but were not required for Rheb activation of mTOR, suggesting that 
inhibitors of these enzymes will not block Rheb activity.  I also studied whether FTS blocks 
Rheb farnesylation and function.  Although FTS failed to inhibit Rheb localization, it 
potently inhibited both Rheb- and mTOR-dependent tumor growth, suggesting that it indeed 
inhibits mTOR and not Rheb.  Therefore, FTS may be a beneficial treatment both for breast 
cancer and other Rheb- and mTOR-dependent tumors.  Together, these studies have 
increased our understanding of the roles of Ras family small GTPases in breast cancer and 
have suggested potentially novel therapeutic strategies to treat breast cancer. 
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CHAPTER 2 
TOOLS TO STUDY THE FUNCTION OF THE RAS-RELATED, ESTROGEN-
REGULATED GROWTH INHIBITOR IN BREAST CANCER1
 
Abstract 
 Rerg (Ras-related, Estrogen Regulated, Growth inhibitor) is a Ras-related small 
GTPase and candidate tumor suppressor.  Rerg gene expression is stimulated by the estrogen 
receptor alpha (ERα) and Rerg gene expression is absent in ERα-negative breast cancers.  
ERα-negative breast cancers are highly invasive and metastastic and are typically more 
advanced than their ERα-positive counterparts.  Like Ras, Rerg binds and hydrolyzes GTP, 
but unlike Ras, Rerg has been shown to possess growth inhibitory activity in breast cancer 
cells.  The precise role that Rerg loss plays in breast cancer growth, and the mechanisms by 
which it does so, are unknown.  In this chapter, we describe tools to detect and manipulate 
the expression of Rerg in breast cancer cells.  We validated the use of an antibody to detect 
Rerg expression by immunohistochemistry analyses of patient tumors and by western blot 
analysis.  We also generated mammalian expression vectors that encode wild-type and 
mutants of Rerg that are altered in GDP/GTP regulation.  Finally, we applied an inducible 
Rerg expression system and utilized a retrovirus-based RNA interference approach to repress 
                                                 
1 Authors: Ariella B. Hanker, Staeci Morita, Gretchen A. Repasky, Douglas T. Ross, Robert S. Seitz, and 
Channing J. Der.  All figures, except for Figure 2-1B, represent the work of Ariella B. Hanker. 
Rerg expression.  These tools provide invaluable reagents for evaluating the biological 
function of Rerg in breast cancer. 
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Introduction 
The Rerg (Ras-related, Estrogen Regulated, Growth inhibitor) small GTPase was 
initially identified in a microarray screen that grouped breast tumor samples into clinically 
relevant subtypes (2, 151).  Rerg gene expression was found to be decreased in the most 
aggressive, ERα-negative subtypes (151).  In fact, Rerg gene expression is directly regulated 
by estrogen.  Recent microarray analyses by Perou and colleagues found that Rerg expression 
levels are a statistically significant predictor of patient outcome, even within ERα-positive 
breast cancers, indicating that low levels of Rerg expression correlate with breast cancer 
progression (personal communication, unpublished observations).  Furthermore, other 
microarray studies have found that Rerg expression is decreased in some metastatic cancers 
compared to their non-metastatic counterparts, including prostate and lung cancer (170-172).  
Rerg expression is also decreased or lost in kidney, ovary, and colon tumor tissues (153).  
These studies suggest that loss of Rerg may be an important step in tumor progression and 
metastasis. 
Rerg belongs to the Ras branch of the Ras superfamily of small GTPases (21).  Rerg 
shares ~42% amino acid sequence identity with the Ras proto-oncogene proteins.  Ras 
functions as a GTP/GDP regulated switch that relays extracellular ligand-stimulated signals; 
these signals regulate cell proliferation, differentiation, and survival.  Ras is mutationally 
activated in 30% of human cancers, but only 5% of breast cancers.  Like Ras, Rerg can bind 
to and hydrolyze GTP and cycles between active GTP-bound and inactive GDP-bound states 
(151).  Whether, like Ras, the GTP-bound form of Rerg is the “active” form is not yet 
known.  Ras binds to and activates its many downstream effectors via its core effector 
domain (Ras residues 32-40).  Key effectors implicated in Ras-mediated oncogenesis include 
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the Raf serine/threonine kinases, the phosphatidylinositol 3-kinases, and guanine nucleotide 
exchange factors for the Ral Ras-like small GTPases (RalGEFs) (38).  Although Rerg shares 
significant sequence identity with the Ras effector domain, no known Ras effectors have 
been shown to bind to Rerg.  Additionally, no Rerg-specific effectors have been identified to 
date.  Finally, while the intrinsic biochemical properties of Rerg suggest that, like Ras, Rerg 
GDP/GTP cycling will be regulated by guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs), Ras GEFs and GAPs are not known to regulate Rerg and 
no Rerg-specific GAPs or GEFs have been identified.   
A major difference between the sequences of Ras and Rerg is in their carboxyl-
terminal sequences.  All Ras proteins terminate in a CAAX (C = cysteine, A = aliphatic 
amino acid, X = terminal amino acid) tetrapeptide sequence, a substrate for farnesyl lipid 
modification responsible for membrane localization and critical for Ras biological activity.  
Rerg lacks this motif, and unlike Ras, Rerg is localized primarily to the cytosol (151).  
Despite their sequence similarity, Rerg and Ras play opposing roles in human 
oncogenesis.  While Ras functions as an oncogene and drives growth transformation and 
tumorigenesis, Rerg exhibits characteristics of a tumor suppressor and impedes tumor 
growth.  Previous studies have shown that ectopic overexpression of Rerg decreases cell 
proliferation and tumorigenesis of Rerg-expressing, ERα-positive MCF-7 breast cancer cells 
(151, 153), further supporting a tumor suppressor function for Rerg in breast cancer.  
However, whether the absence of Rerg expression directly contributes to breast cancer 
advancement, and whether restoring Rerg expression in ERα-negative breast cancers limits 
their tumorigenicity and aggressiveness, has not yet been determined.  Here, we describe our 
development and validation of tools to detect and manipulate the expression of the unique 
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GTPase Rerg in breast cancer cells.  We have developed and validated antibodies that detect 
ectopic and endogenous Rerg expression by western blot and immunohistochemical staining.  
We have constructed mammalian expression vectors for expression of wild type and mutant 
Rerg proteins.  We have generated a tamoxifen-inducible ERα-Rerg fusion protein to 
inducibly express Rerg in ERα-negative breast cancers and have used this system to study the 
effects of Rerg on cell growth and invasion.  Finally, we have generated retrovirus vectors 
for interfering short hairpin RNA (shRNA) to silence endogenous Rerg expression in ERα-
positive breast cancers.  These reagents will undoubtedly prove useful in identifying and 
studying the precise biological function of Rerg in normal cells as well as in breast and other 
human cancers.  
 
Materials and Methods 
Molecular Constructs 
cDNA sequences encoding Rerg wild-type (wt), Rerg S20N, and Rerg Q64L cDNA 
sequences in the pKH3 expression vector plasmids (generous gifts of D. Andres, University 
of Kentucky) were used as templates for polymerase chain reaction (PCR)-mediated DNA 
amplification to generate open reading frame cassettes for subcloning into the pCGN-hygro 
mammalian cell expression vector.  Expression of the inserted cDNA is controlled from the 
cytomegalovirus promoter and the vector encodes for hygromycin resistance for selection of 
stably-transfected cells.  The cassettes contained 5’ and 3’ BamHI sites to allow subcloning 
downstream of and in frame with sequences encoding the hemaglutinin (HA)-epitope tag.  
Briefly, PCR-generated products and pCGN-hygro plasmid were digested with BamHI to 
generate sticky ends.  BamHI-digested pCGN-hygro was then dephosphorylated with shrimp 
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alkaline phosphatase (SAP) to prevent religation of the plasmid.  The BamHI-digested PCR 
product was then incubated with BamHI-digested and SAP-treated pCGN-hygro using the 
Rapid DNA Ligation kit (Roche Applied Science, Indianapolis, IN).  Competent DH5α E. 
coli were then transformed with the ligation products and positive clones were identified by 
restriction digest analyses.  The Rerg cDNA sequences were verified for accuracy by DNA 
sequencing.     
 For the generation of retrovirus-base expression vectors the Rerg wild-type (WT), 
Rerg Q64L, and Rerg S20N cDNA sequences were subcloned into the pBabe HAII retrovirus 
vector.  This vector is a variant of the pBabe-puro retrovirus expression vector (173) that has 
been modified to include coding sequences for the HA epitope sequence that are added to the 
amino terminus of the inserted cDNA sequence (174).  Expression of the inserted cDNA 
sequence is controlled by the Moloney leukemia virus long terminal repeat promoter and the 
vector encodes for puromycin resistance for selection of stably-transfected or -infected cells.  
pCGN Rerg WT, Q64L, or S20N plasmid DNAs were digested with BamHI and the resulting 
Rerg cDNA fragments were ligated in-frame into linearized pBabe HAII vector (as described 
above).   
pBabe ER expression vectors encoding wild-type or Q64L and S20N mutants of Rerg 
were generated for tamoxifen-inducible expression of wild-type and mutant ER-Rerg fusion 
proteins.  In these constructs, the cDNA sequence for the ligand binding domain of the ERα 
is placed 5’ to the Rerg cDNA coding sequence.  pCGN Rerg plasmid DNAs were used as 
templates for PCR-mediated DNA amplification to generate open reading frame cassettes 
containing 5’ and 3’ EcoRI restriction sites.  The primers used were: 5’ 
TTTTGAATTCATGGCTAAAAGTGCGG 3’ and 5’ 
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TTTTGAATTCTTTCTAACTACTGATTTTG  3’.  PCR products were digested with EcoR1 
and Rerg fragments were ligated into the Zero Blunt Topo Kit (Invitrogen, Carlsbad, CA).  
Rerg was then excised from the Zero Blunt Topo vector and ligated into the EcoR1 site of the 
linearized pBabe ER vector (derived from the pBabe ER-H-Ras vector). 
Rerg shRNA Constructs  
For generation of short hairpin RNA (shRNA) against Rerg, we selected target 
sequences using the web server at http://jura.wi.mit.edu/bioc/siRNA.  We chose three target 
sequences for generation of shRNA Rerg expression vectors.  However, our subsequent 
analyses found that target 2 showed no knockdown activity against Rerg and will not be 
discussed here.  The target sequence for Rerg shRNA 1 corresponds to nucleotide residues 
2115-2137 in the 3’ untranslated region of Rerg cDNA, whereas the Rerg shRNA 3 target 
sequence corresponds to nucleotide residues 427-449 in the coding sequence.  The following 
oligonucleotides were used for insertion into the BglII and HindIII sites of the 
pSUPER.retro.puro vector: 5’-
GATCCCCAGCGTTAGCGGCATTAATTTTCAAGAGAAATTAATGCCGCTAACGCTT
TTTTGGAAA-3’ and 5’-
AGCTTTTCCAAAAAAGCGTTAGCGGCATTAATTTCTCTTGAAAATTAATGCCGCT
AACGCTGGG-3’ for Rerg shRNA 1 and 5’-
GATCCCCGCAACCATCGATGATGAAGTTCAAGAGACTTCATCATCGATGGTTGCT
TTTTGGAAA-3’ and 5’-
AGCTTTTCCAAAAAGCAACCATCGATGATGAAGTCTCTTGAACTTCATCATCGAT
GGTTGCGGG-3’ for Rerg shRNA 3.  Oligonucleotides were phosphorylated and annealed 
prior to ligation into the BglII and HindIII sites of the pSUPER.retro.puro vector 
44
(Oligoengine, Seattle, WA), as described previously (175).  The negative control 
pSUPERIOR.retro.puro GFP shRNA (176) was a gift from Natalia Mitin (UNC-Chapel Hill).  
All inserted oligonucleotide sequences in these molecular constructs were verified by 
sequencing.  
 
Cell Culture and Expression Vector Transfection and Infection 
293T human embryonic kidney epithelial cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 100 
units/mL penicillin and 100 μg/mL streptomycin in a 10% CO2 humidified incubator at 37ºC.  
All human breast carcinoma cell lines, with the exception of the SUM149 cells, were 
obtained from the American Type Culture Collection and cultured as described previously 
(29).  The SUM149 basal-like breast carcinoma cell line (obtained originally from Stephen 
Ethier, Karmanos Cancer Institute), and provided by Carolyn Sartor, UNC-Chapel Hill) was 
grown in Ham’s F12 medium supplemented with 5% FCS, 5 μg/mL insulin, 1 μg/mL 
hydrocortisone, 0.5 μg/mL fungizone, and 5 μg/mL gentamycin.  All breast cancer cells were 
grown in a 5% CO2 incubator at 37ºC. 
Sub-confluent cultures of each cell line were transfected with the various Rerg or 
shRNA expression plasmid DNAs using Lipofectamine and Plus reagents (Invitrogen) 
according to the manufacturer’s instructions.  Cells were harvested 24 h following 
transfection. 
All retroviral infections were performed as described previously (175).  Briefly, 293T 
host cells were transfected by calcium chloride precipitation with 10 μg of the pCL10A1 
virus packaging vector plasmid DNA along with 10 μg of the appropriate Rerg or shRNA 
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expression plasmid DNA.  The medium was replaced 16 h prior to infection of target cells.  
Two days following 293T transfection, host cells were infected with filtered virus-containing 
medium from the 293T cells supplemented with 8 μg/mL polybrene to increase infection 
efficiency.  Twenty-four to forty-eight h following infection, growth medium supplemented 
with puromycin was used for the selection of stably-infected T-47D (2 μg/mL), MDA-MB-
231 and Hs578T (1 μg/mL), and SUM149 (0.5 μg/mL) cells.  After selection, multiple drug-
resistant colonies (>100) were pooled together to establish mass populations of stably-
infected cells.  All stable cell lines were maintained in medium supplemented with 
puromycin.  
 
Cell Growth and Invasion Assays 
For the MTT cell viability assay, MDA-MB-231 cells stably expressing ER-Rerg 
fusion proteins were seeded at 2 x 103 cells per well in growth medium.  Cells were seeded in 
replicates of eight in 96-well plates and allowed to attach overnight.  The growth medium 
was then removed and replaced with fresh growth medium supplemented with 1 μM 4-
hydroxytamoxifen (4-OHT) to induce ER-Rerg expression.  For each time point, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, St. Louis, 
MO), which stains only viable cells, was added to a final concentration of 0.5 mg/mL in the 
media of each well and plates were incubated for 4 h.  The formazan (MTT metabolic 
product) was then resuspended in 100 μL dimethyl sulfoxide (DMSO) and the optical density 
was measured at 560 nM using an ELx100 Universal Microplate Reader (Bio-Tek 
Instruments, Inc., Winooski, VT).  Optical density directly correlates with cell quantity.   
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The transwell Matrigel invasion assay using the Biocoat Matrigel Invasion Chamber 
(BD Biosciences, Bedford, MA) was performed according to the manufacturer’s instructions. 
Briefly, MDA-MB-231 stable cell lines were seeded at 5 x 103 cells per chamber in triplicate 
in serum-free DMEM supplemented with 1% fatty acid-free bovine serum albumin (BSA).  
Medium containing 3% FCS was added to each bottom well of a 24-well plate to serve as a 
chemoattractant.  After two h, growth medium supplemented with ethanol (vehicle) or 1 μM 
4-OHT was added to each chamber and bottom well.  After an additional 22 h incubation at 
37ºC, non-invading cells were removed with a cotton swab and invading cells were fixed and 
stained using Diff-Quick Stain Set (Dade Behring).  Invading cells were quantified by 
counting 5 fields of view using the 20x objective lens under an inverted phase contrast 
microscope.  
The soft agar assay to evaluate anchorage-independent growth potential was 
performed as described previously (177).  Briefly, 104 SUM149 cells stably expressing ER-
Rerg or H-Ras fusion proteins were seeded in triplicate in 60 mm plates into growth medium 
supplemented with 0.4% bacto-agar and overlaid onto a bottom layer containing growth 
medium supplemented with 0.6% agar.  Agar layers contained SUM149 growth medium 
supplemented with 10% FCS and penicillin/streptomycin.  Either ethanol (vehicle) or 1 μM 
4-OHT final concentration was added to both top and bottom layers.  Media containing 
ethanol or 1 μM 4-OHT was replaced twice weekly for three weeks.  After 21 days, viable 
colonies were stained in 2 mg/mL MTT and plates were scanned.  Visible colonies were 
counted from scanned images on Adobe Photoshop. 
 
Generation of Anti-Rerg Antibodies  
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The S0222 anti-Rerg antiserum was raised in rabbits to bacterially-expressed His6-
thioredoxin-Rerg fusion protein from the pET32a-Rerg E. coli expression vector (151).  The 
S0068 antiserum was raised against a 21-mer peptide corresponding the carboxyl-terminus of 
RERG (residues 179-199; RRSSTTHVKQAINKMLTKISS) conjugated to keyhole limpet 
hemocyanin (KLH) by EDC coupling.  The protein or KLH conjugated peptide was mixed 
with Freund's adjuvant, injected and serially boosted into two New Zealand white rabbits 
over a 14 week period.  The boosts were made approximately three weeks apart.  Antisera 
were collected and affinity purified by attaching the recombinant protein or peptide to 
Sepharose 4B.  Antibody was eluted by a pH gradient of glycine-HCL pH 4 decreasing to pH 
2 in borate buffer.   
 
Results and Discussion 
Validation of S0222 Anti-Rerg Antibody for Western Blot Analyses  
In order to determine whether the S0222 anti-Rerg antibody can detect endogenous 
human Rerg protein expression, we first tested it against ectopically expressed Rerg.  We 
determined that the optimum dilution for western blot analyses was 1:500 (final 
concentration of 740 ng/mL) in 5% non-fat dry milk/TBST, incubated overnight.  S0222 
effectively detected expression of HA-Rerg (Figures 2-1A and 2-2B).  Furthermore, S0222 
detected expression of the ER-Rerg fusion protein (Figure 2-3).  However, S0222 was not as 
sensitive as the HA.11 antibody (Covance, Berkeley, CA) for detection of HA-Rerg (Figure 
2B) and typically required longer exposure.   
Next, we asked whether S0222 could detect endogenous Rerg expression.  To test 
this, we generated lysates from ERα-positive and ERα-negative breast cancer cells treated 
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Figure 2-1. Antibody detection of endogenous Rerg expression in breast cancer cell lines 
and tumor tissue. (A) Detection of endogenous Rerg expression in breast carcinoma cell lines.  
Endogenous Rerg and ectopically-expressed HA-tagged Rerg were detected in breast cancer 
cells by western blot analysis using the S0222 anti-Rerg antibody.  The indicated cell lines were 
incubated in complete growth media, either with or without 10 nM 17β-estradiol (E2, Sigma), for 
24 h.  A strong band at ~26 kDa (asterisk) was seen in all Rerg mRNA-positive cell lines (BT-474, 
MCF-7 and T-47D), whereas a band at ~30 kDa (arrow) was detected in MDA-MB-231 cells 
stably-infected with the pBabe-puro HAII Rerg plasmid.  Blot analysis for β-actin (Sigma) was 
used as a loading control.  (B) Rerg expression levels correlate with ERα expression in breast 
cancer tissue.  Rerg and ERα protein expression in primary invasive breast tissues were detected 
by IHC analyses.  Parallel staining is shown for Rerg (S0068) and ERα from four representative 
samples.  Adapted from Hanker et al., Methods Enzymol 2008;439:53-72.  Panel B is the work of 
Douglas Ross and Robert Seitz (Applied Genomics Inc.).
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with 10 nM 17β-estradiol (Sigma-Aldrich) for western blot analysis with S0222.  We 
previously showed that Rerg mRNA was detected in ERα-positive, but not ERα-negative, 
breast cancer cells (151).  In the ERα-positive cell lines, S0222 detected a band at the proper 
molecular weight (Figure 2-1A).  However, a weaker band at a similar weight was also seen 
in Hs578T and MDA-MB-231 cells (Figure 2-1A), two cell lines that were negative for Rerg 
mRNA by northern blot analyses and reverse transcription (RT)-PCR (data not shown).  It is 
possible that the S0222 antibody is cross-reacting with another protein of a similar size in 
these samples.  We are fairly certain that the band seen in the ERα-positive samples is indeed 
endogenous Rerg, as knocking down Rerg gene expression by shRNA decreased the intensity 
of this band (Figure 2-5C).  We did not find that treatment with estradiol stimulated an 
increase Rerg expression (Figure 2-1A), perhaps because the cells were maintained in 
phenol-red containing medium and were not estrogen-starved.  Since phenol red can 
stimulate the ERα, Rerg may have been expressed at maximal levels even in cells not directly 
stimulated with estrogen.  Taken together, these results suggest that the S0222 antibody can 
effectively detect endogenous Rerg expression by western blot analysis. 
 
Use of S0068 Anti-Rerg Antibody for Immunohistochemical Staining of Breast Tumor Tissue  
The tissue source and our protocols for immuohistochemical (IHC) staining of 
paraffin-embedded primary invasive breast tumor tissues array blocks have been described in 
detail elsewhere (178).  Briefly, prior to staining, tissue arrays were de-paraffinized and 
dehydrated by submerging in xylene three times for 10 min each. Tissue arrays were then 
rinsed three times in 100% ethanol and twice in 95% ethanol and treated by microwaving 
boiling for 11 min in 10 μM buffered citrate (pH 6.0).  Slides were allowed to cool to room 
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temperature and rinsed in distilled water followed by phosphate-buffered saline (PBS).  
Slides were dipped in 0.03% hydrogen peroxide, rinsed with PBS, and then stained using 
dilutions of antibodies in DAKO Diluent (DAKO Cytomation Inc.) for 1 h at room 
temperature. Secondary antibody was applied for 1 h and staining was visualized using the 
DAKO Cytomation Envision staining kit according to the manufacturer’s instructions. 
Staining with an antibody directed against ERα was performed by a commercial service (US 
Labs Inc.). 
Anti-Rerg (S0068) and anti-ERα staining was executed in parallel using slides 
comprised of tissue from primary invasive breast cancers.  Consistent with array analyses in 
breast tumors and western blot analyses of breast tumor cell lines (151), the intensity of anti-
Rerg staining correlated with that of ERα.  Additionally, whereas ERα staining is nuclear, 
Rerg staining is cytosolic, as we have seen in cell lines.  These results provide validation for 
the use of S0068 anti-Rerg antibody for IHC analyses. 
 
Transient and Stable Expression of Wild-Type and Mutant Rerg Proteins  
Like Ras, Rerg cycles between GTP- and GDP-bound states (151), but whether 
GDP/GTP cycling is important for Rerg function is not known.  In order to determine 
whether Rerg function depends on its GTP-bound state, we introduced missense mutations 
that resulted in amino acid substitutions in Rerg, based on analogous mutants of Ras proteins, 
that render Rerg either constitutively GTP-bound (Rerg Q64L) or preferentially bound to 
GDP (Rerg S20N).  The Rerg Q64L mutation is analogous to the GAP-insensitive Q61L 
mutation in Ras and has been shown previously to possess decreased intrinsic GTPase 
activity in vitro (151).  Since no GAP specific for Rerg has been identified, whether this 
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mutant is also impaired in GAP-stimulated hydrolysis is not known.  However, in vitro 
biochemical analyses support the existence of a GAP (151).  The Rerg S20N mutant has not 
been described previously but is based on the preferentially GDP-bound S17N mutation in 
Ras (179).  Introduction of the analogous mutation has generated dominant negative variants 
of a wide variety of Ras superfamily proteins.  Such dominant negatives function by forming 
nonproductive complexes with GEFs that stimulate the activation of the wild-type GTPase.  
While a Rerg-specific GEF remains to be identified, an indirect evaluation of such mutants 
can be performed by expressing them in cells.  For example, the growth suppressive activity 
of the Ras S17N mutant is consistent with the requirement for Ras in normal cell 
proliferation.  Therefore, if Rerg functions as a tumor suppressor, then dominant negative 
Rerg would be expected to stimulate growth in cells in which Rerg is expressed.   
In order to test the expression of these mutants in the pCGN-hygro vector, we 
transiently transfected 293T cells with pCGN-hygro expression vectors encoding Rerg wild-
type, Q64L, or S20N.  As shown in Figure 2A, wild-type Rerg and Rerg Q64L were 
expressed at high levels, but expression of Rerg S20N was substantially reduced.  Similar 
expression patterns were observed when these constructs were stably expressed in breast 
cancer cells (data not shown).  We also tested expression of pBabe HA-tagged Rerg 
constructs stably expressed in Hs578T breast cancer cells.  Wild-type Rerg and Rerg Q64L 
were expressed at equal levels, but Rerg S20N expression was not detected (Figure 2-2B).  
Furthermore, we consistently failed to detect transient expression of pBabe-Rerg S20N in 
293T cells (data not shown) and ER-Rerg S20N expression was not efficiently induced 
(Figure 2-3).  Thus, we found that Rerg S20N protein was inefficiently expressed regardless 
of the expression vector or cell line used, or whether we tried transient or stable expression.  
52
Figure 2-2.  Transient and stable expression of wild-type and mutant Rerg proteins. (A) 
Transient expression of HA-Rerg proteins in 293T cells. 293T cells were transfected with the 
empty pCGN-hygro plasmid (Vector), or encoding Rerg WT, Rerg Q64L, or Rerg S20N.  HA-Rerg
expression was detected using the HA.11 (Covance) anti-HA epitope antibody.  (B) Stable 
expression of HA-Rerg proteins in ER-negative Hs578T cells.  Western blot analysis to verify 
expression of ectopically-expressed Rerg proteins was performed for Hs578T cells stably-infected 
with the empty pBabe-puro HAII vector, or encoding Rerg WT, Rerg Q64L, or Rerg S20N.  The 
lysates were blotted with either anti-HA epitope or S0222 anti-Rerg antibody.  Blot analysis with 
anti-β-actin was used as a loading control to verify equivalent total protein.  Adapted from Hanker 
et al., Methods Enzymol 2008;439:53-72.
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We believe that the reduced expression level is most likely due to decreased protein stability. 
The mutation in residue 20 may disrupt Rerg protein structure.  Alternatively, the mutation 
may decrease GDP- and GTP-binding, which may account for the reduced protein stability.  
The future identification of a Rerg GEF will be required to address these issues.  Future 
directions may include the generation of additional Rerg mutants as candidate dominant 
negatives.   
 
Establishment of a Tamoxifen-inducible Rerg Protein Expression System 
 A major obstacle in the study of tumor suppressors and other growth inhibitory 
proteins is that their stable expression is not well tolerated in cells.  Either toxicity prevents 
suitable long-term expression, or cells overcome growth inhibition by secondary, 
compensatory mechanisms.  In order to evade these scenarios and to obtain a more accurate 
measure of Rerg growth inhibition, we generated an inducible expression system for Rerg. 
We constructed a chimeric gene that encodes a tamoxifen-inducible ER-Rerg fusion protein.  
This fusion protein is composed of a mutant form of the ERα ligand binding domain, that 
responds only to 4-hydroxytamoxifen (4-OHT) and not to phenol red or estrogen, and is 
fused to the N-terminus of full-length Rerg.  In the absence of tamoxifen, the fusion protein 
is inactive because it is bound by an Hsp90 complex and degraded.  Upon ligand binding, the 
Hsp90 complex dissociates, allowing stable expression of the fusion protein (180).  The use 
of ERα fusion proteins to generate inducible protein expression has been described for Ras 
and many other signaling proteins (180-184).  While it is possible that addition of the ERα 
sequences to the amino terminus of Rerg may disrupt Rerg function, previous observations 
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with Ras and other Ras superfamily proteins indicate that the addition of sizeable sequences 
to the amino termini of small GTPases generally does not cause perturbations in function. 
To determine whether ectopic expression of Rerg in ERα-negative breast cancer cells 
decreases their tumorigenicity, we retrovirally infected two ERα-negative cell lines, MDA-
MB-231 and SUM149, with the empty pBabe-puro plasmid (Vector), or with plasmids 
encoding ER-Rerg WT, Q64L, or S20N.  To induce ER-Rerg protein expression, we treated 
stably-infected cells with 1 μM 4-OHT for a minimum of 24 h.  Figure 2-3 shows that in both 
cell lines, tamoxifen treatment efficiently induced expression of wild-type Rerg and Rerg 
Q64L in both cell lines.  In contrast, Rerg 20N was not induced efficiently.  Some leakiness 
of expression was observed in untreated cells when the film was exposed for a longer time 
period (Figure 2-3A).  Despite this leakiness, it is clear that tamoxifen treatment greatly 
enhanced ER-Rerg protein expression in this system.  Furthermore, H-Ras 12V expression 
was also efficiently induced by 1 μM 4-OHT in SUM149 cells (Figure 2-3B). 
We next asked whether inducing Rerg expression decreases the growth or invasive 
properties of the two ERα-negative breast cancer cell lines.  First, we used an MTT assay to 
measure the anchorage-dependent cell proliferation rate of MDA-MB-231 cells stably 
expressing ER-Rerg wt, Q64L, and S20N.  Figure 2-4A shows that inducing wild-type or 
mutant Rerg with 4-OHT did not significantly alter the viability or proliferation rate of 
MDA-MB-231 cells.  Next, we used the Matrigel invasion assay to determine whether 
inducing wild-type or mutant Rerg decreased the invasiveness of MDA-MB-231 cells in 
vitro.  Adding 4-OHT to cell lines stably-infected with the empty pBabe-ER plasmid 
(Vector), or with plasmids encoding ER-Rerg WT, Q64L, or S20N, did not significantly and 
reproducibly affect invasion through Matrigel in vitro (Figure 2-4B).  In addition, we did not 
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Figure 2-3.  Tamoxifen-inducible expression of an ER-Rerg fusion protein. The plasmids 
encoding ER-Rerg fusion proteins were retrovirally infected into (A) MDA-MB-231 cells and (B) 
SUM149 cells.  Stable cell lines were treated with either vehicle (ethanol) or 1 μM 4-
hydroxytamoxifen (4-OHT) for 3 days (A) or 1 day (B).  Western blot analysis using the S0222 anti-
Rerg antibody detected a ~55 kDa band corresponding to the ER:Rerg fusion protein in samples 
treated with 4-OHT.  Similar results were obtained when cells were treated with 4-OHT for 7 days 
(data not shown).  As a control for 4-OHT induction, SUM149 cells stably-infected with an 
expression vector encoding the ER-H-Ras G12V protein (C) was included.  Expression was 
induced by 1 day treatment with 4-OHT and detected by western blot analysis with an H-Ras
antibody (#146; Quality Biotech, Camden, NJ).  Blot analysis for β-actin in total cell lysates was 
used as a loading control to verify equivalent total protein.  Adapted from Hanker et al., Methods 
Enzymol 2008;439:53-72.
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observe significant differences in soft agar growth or invasion through collagen in these cell 
lines (data not shown).  Together, these data show that Rerg expression does not significantly 
affect the growth or invasive properties of ERα-negative MDA-MB-231 breast cancer cells. 
We also examined whether inducing Rerg expression affected the growth of SUM149 
cells.  We used a soft agar assay to measure the anchorage-independent growth of these cells 
stably expressing ER-Rerg and ER-H-Ras constructs.  As expected, treating vector control 
cells with 4-OHT did not affect their ability to grow in soft agar.  Furthermore, as we 
expected, inducing oncogenic H-Ras G12V with 4-OHT drastically increased the ability of 
these cells to form colonies in soft agar (Figure 2-4C).  However, inducing wild-type Rerg or 
Rerg Q64L did not significantly affect their anchorage-independent growth.  Inducing Rerg 
S20N may have slightly increased the anchorage-independent growth of these cells; this may 
be because Rerg S20N can act as a dominant negative and may inhibit Rerg exchange factors 
in these cells.  Thus, consistent with results obtained with the MDA-MB-231 cell line, 
inducing Rerg expression did not significantly reduce the anchorage-independent growth of 
the ERα-negative SUM149 breast cancer cells. 
We have shown previously that ectopic overexpression of HA-tagged Rerg decreases 
cell proliferation and soft agar growth of the Rerg-expressing MCF-7 breast cancer cell line 
(151).  However, Rerg did not show significant growth inhibition when ectopically expressed 
in the two ERα-negative cell lines we tested.  This discrepancy may be due to overexpression 
artifacts—in our previous studies, Rerg was expressed from the CMV promoter, which drives 
expression much more strongly than the pBabe promoter described here.  Another possibility 
is that the growth inhibitory function of Rerg may be cell-type specific; Rerg may act as a 
growth inhibitor in ERα-positive but not in ERα-negative cells.  Alternatively, it remains 
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Figure 2-4.  Effects of induction of ER-Rerg expression on growth and invasive properties 
in ER-negative breast cancer cells. (A) Evaluation of growth rate upon induction of ER-Rerg
expression in MDA-MB-231 cells.  Cells were incubated in growth medium supplemented with 1 
μM 4-OHT to induce Rerg expression.  MTT was added and optical density was measured at the 
indicated time points.  Results are an average of eight replicates per time point; error bars 
represent standard deviation.  (B) Evaluation of Matrigel invasion upon induction of ER-Rerg in 
MDA-MB-231 cells.  Stable cell lines were seeded in triplicate and allowed to invade towards 
growth medium supplemented with 3% FCS (chemoattractant).  After two h, growth media 
supplemented with ethanol (Vehicle) or 1 μM 4-OHT was added to each top and bottom well to 
induce Rerg expression.  After incubation for 22 h, non-invading cells were removed and invading 
cells were fixed and stained.  Invading cells were quantified by counting five fields of view using the 
20x objective lens under a phase contrast microscope.  Error bars represent standard deviation of 
triplicate wells.  (C) Evaluation of anchorage-independent growth upon induction of ER-Rerg in 
SUM149 cells.  Cells were seeded in triplicate into 0.4% soft agar over a 0.6% bottom layer; 
ethanol (Vehicle) or 1 μM 4-OHT was added to the top and bottom agar layers.  After 21 days,
viable colonies were stained in 2 mg/mL MTT and visible colonies representing >50 cells were 
quantified.  Results represent the average of triplicate plates; error bars represent standard 
deviation.  Adapted from Hanker et al., Methods Enzymol 2008;439:53-72.
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possible that the large ERα domain fused to Rerg is disrupting its function.  However, we 
believe this is not the case for the following reasons: 1) placing an HA tag N-terminal to 
Rerg does not disrupt its growth inhibitory function, and 2) placing the ERα ligand binding 
domain N-terminal to Ras does not disrupt Ras function (180, 184).  Therefore, although we 
were unable to identify an assay for Rerg function, we believe that the ER-Rerg fusion 
proteins generated here will be very useful in the study of Rerg as other functions are 
identified in the future. 
 
Suppression of Rerg Expression by RNA Interference 
To further define the role of Rerg in breast cancer, we used interfering shRNA to 
repress Rerg in Rerg-expressing cells.  First, we validated that our Rerg shRNA construct 
reduced expression of ectopically expressed Rerg protein in 293T cells.   Of the two 
constructs described here, only pSUPER.retro Rerg shRNA 3 targets a sequence in the 
coding region of Rerg.  This construct efficiently reduced expression of pBabe HAII Rerg 
(Figure 2-5A), verifying that Rerg shRNA3 does indeed target Rerg mRNA. 
 Next we generated mass populations of the T-47D ERα-positive cell line stably-
infected with either the empty pSUPER.retro.puro vector, or encoding Rerg shRNA 1, Rerg 
shRNA 3, or GFP shRNA. After selection in growth medium supplemented with puromycin, 
multiple drug-resistant colonies were pooled together to establish cell lines for biological 
analyses.  To determine whether the Rerg shRNA constructs efficiently reduced endogenous 
Rerg mRNA levels, we used quantitative real-time RT-PCR.  RNA was isolated from each T-
47D cell line using the TRIzol reagent (Invitrogen) and genomic DNA was removed by 
treatment with RQ1 DNase (Promega, Madison, WI).  mRNA was reverse-transcribed to 
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Figure 2-5.  Repression of Rerg expression by shRNA. (A) Reduction of ectopically expressed 
Rerg by shRNA.  293T cells were transiently co-transfected with either 2.5 μg of the empty 
pSUPER.retro.puro vector (lanes 1, 2) or encoding Rerg shRNA 3 (lane 3), together with 0.5 μg
the empty pBabe-puro HAII vector (lane 1) or encoding HA-Rerg (lanes 2, 3).  HA-Rerg expression 
was detected by immunoblotting with the anti-HA or anti-Rerg (S0222) antibodies.  Blot analysis for 
β-actin was used to verify equivalent total protein.  (B) shRNA-induced reduction of endogenous 
Rerg mRNA.  cDNA from T-47D cells stably-infected with the empty pSUPER.retro.puro vector, 
Rerg shRNA 1, Rerg shRNA 3, or GFP shRNA was evaluated using quantitative real-time RT-
PCR.  Samples were run in duplicate.  Rerg:actin ratio was determined using the equation 2ΔCT, 
where ΔCT = β-actin CT value – Rerg CT value.  (C) shRNA-mediated reduction of endogenous 
Rerg protein.  T-47D cells stably-infected with the empty pSUPER.retro.puro vector, or encoding 
Rerg shRNA 1, Rerg shRNA 3, or GFP shRNA, or the pBabe-puro HAII-Rerg expression vector, 
were lysed and analyzed by western blot.  The S0222 anti-Rerg antibody was used to detect Rerg
expression.  Blot analysis for β-actin was used as a loading control.  Adapted from Hanker et al., 
Methods Enzymol 2008;439:53-72.
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cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen).  Rerg cDNA was 
amplified using Absolute SYBR Green ROX Mix (ABGene House, Surrey, UK) and the 
following primers specific to Rerg cDNA: 5’ GGCATCTTCACCTTGCTTT 3’ (sense) and 
5’ GGCATGGTTAAGCTCCATT 3’ (antisense).  Real-time RT-PCR was performed on the 
ABI PRISM real-time PCR machine (Applied Biosystems, Foster City, CA) using the SYBR 
green detector and data was analyzed using SDS 2.0 software.  Both Rerg shRNA sequences 
significantly reduced expression of Rerg mRNA (Figure 2-5B).  Similar results were 
obtained with semi-quantitative RT-PCR (data not shown) 
We used western blot analysis with the S0222 anti-Rerg antibody to determine 
whether the Rerg shRNA constructs could reduce the expression of endogenous Rerg protein.  
As shown in Figure 2-5C, Rerg shRNA 3, but not Rerg shRNA 1, decreased expression of 
endogenous Rerg protein.  We cannot explain why Rerg shRNA 1 reduced expression of 
Rerg mRNA but not Rerg protein.  Consistent with our results from inducing Rerg 
expression, knocking down endogenous Rerg expression did not significantly affect soft agar 
growth or Matrigel invasion of the T-47D breast cancer cells (data not shown).  These studies 
do not support a critical role for Rerg in breast cancer growth or invasion. 
 
Summary 
 In this chapter, we have described reagents for inducible, transient, or sustained 
expression of ectopic Rerg or to reduce endogenous Rerg expression in breast cancer cells.  
We have also described antibodies that detect Rerg expression by western blot or IHC 
analyses. We have validated expression of putative gain-of-function and loss-of-function 
Rerg mutants.  While inducing Rerg expression or knocking down Rerg by shRNA did not 
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significantly affect the in vitro growth or invasive properties of the breast cancer cell lines we 
tested, it remains possible that Rerg expression will impair the tumorigenic, invasive or 
metastatic properties of breast carcinoma cells when evaluated in mouse models.  The 
reagents described here will prove to be useful in identifying a function for Rerg and for 
delineating its role in breast cancer progression. 
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CHAPTER 3 
REQUIREMENT OF CAAX-MEDIATED POSTTRANSLATIONAL PROCESSING FOR 
RHEB LOCALIZATION AND SIGNALING2
Abstract 
The Rheb1 and Rheb2 small GTPases and their effector mTOR are aberrantly 
activated in human cancer and are attractive targets for anti-cancer drug discovery.  Rheb is 
targeted to endomembranes via its C-terminal CAAX (C = cysteine, A = aliphatic, X = 
terminal amino acid) motif, a substrate for posttranslational modification by a farnesyl 
isoprenoid.  Following farnesylation, Rheb undergoes two additional CAAX-signaled 
processing steps, Rce1-catalyzed cleavage of the AAX residues and Icmt-mediated 
carboxylmethylation of the farnesylated cysteine.  However, whether these post-prenylation 
processing steps are required for Rheb signaling through mTOR is not known.  We found 
that Rheb1 and Rheb2 localize primarily to the endoplasmic reticulum and Golgi apparatus.  
We determined that Icmt and Rce1 processing is required for Rheb localization, but is 
dispensable for Rheb-induced activation of the mTOR substrate p70 S6 kinase (S6K).  
Finally, we evaluated whether farnesylthiosalicylic acid (FTS) blocks Rheb localization and 
function.  Surprisingly, FTS prevented S6K activation induced by a constitutively active 
mTOR mutant, indicating that FTS inhibits mTOR at a level downstream of Rheb.  We 
                                                 
2 Authors: Ariella B. Hanker, Rhonda S. Wilder, Elizabeth Petri Henske, Fuyuhiko Tamanoi, Adrienne D. Cox, 
and Channing J. Der.  All data shown represent the work of Ariella B. Hanker. 
conclude that inhibitors of Icmt and Rce1 will not block Rheb function, but FTS could be a 
promising treatment for Rheb- and mTOR-dependent cancers. 
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Introduction 
Rheb is a member of the Ras branch of the Ras superfamily of small GTPases and is 
evolutionarily conserved from yeast to humans (83).  The two mammalian Rheb isoforms, 
Rheb1 (Rheb) and Rheb2 (RhebL1; 51% identity), function as GTP/GDP regulated binary 
switches.  Although both are expressed in many tissues and tumor types, current knowledge 
of Rheb comes largely from the study of Rheb1.  Like Ras, Rheb proteins cycle between 
activated, GTP-bound and inactive GDP-bound states.  Rheb is negatively regulated by the 
tumor suppressor TSC1 (hamartin)-TSC2 (tuberin) complex which functions as a GTPase 
activating protein (GAP) towards Rheb (185).   
 Rheb is a critical component of the phosphatidylinositol 3-kinase (PI3K)-Akt-TSC-
mTOR pathway which is frequently hyperactivated in cancer.  PI3K activates Akt, which 
phosphorylates and inactivates TSC2, leading to an increase in GTP-bound Rheb (185).  
Rheb-GTP is an activator of the rapamycin-sensitive mTOR complex 1 (mTORC1) (90), 
which regulates the initiation of protein translation, nutrient sensing, and cell growth.  mTOR 
controls protein synthesis by phosphorylating proteins involved in translation initiation, such 
as the p70 ribosomal S6 kinase (S6K).   
Loss-of-function germline mutations in TSC1 or TSC2 cause Rheb hyperactivation 
and tuberous sclerosis complex disease which is characterized by the formation of 
hamartomas in a variety of organs (87, 88).  Rheb and mTOR are also hyperactivated in 
many sporadic cancers due to mutations in PI3K and PTEN.  Rheb1 and Rheb2 are 
overexpressed in a variety of tumors, including glioma, oral squamous cell carcinoma, and 
breast, prostate, lung, colon, and ovarian cancer (114-118).  In addition, a Rheb mutation has 
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been found in colon cancer (119), and the RHEB gene is amplified in some prostate cancers 
(118). Therefore, Rheb inhibition may be therapeutically beneficial for a variety of cancers.  
Like Ras, Rheb terminates in a C-terminal CAAX motif (C = cysteine, A = aliphatic, 
X = terminal amino acid), a substrate for farnesyltransferase (FTase)-catalyzed 
posttranslational modification by a C15 farnesyl isoprenoid lipid (83).  Two additional 
CAAX-signaled posttranslational processing steps, proteolytic cleavage of the AAX residues 
[catalyzed by Ras converting enzyme (Rce1)] and carboxylmethylation [(catalyzed by 
isoprenylcysteine carboxyl methyltransferase (Icmt)], are required for Rheb localization 
(186).  However, whether these processing steps are also required for Rheb signaling through 
mTOR is not yet known. 
The CAAX-signaled modifications are necessary but not sufficient for the proper 
membrane association and subcellular localization of a majority of Ras and Rho family small 
GTPases (27, 50).  In addition, a second membrane-targeting signal positioned in sequences 
immediately upstream of the CAAX motif is required.  For example, in H-Ras, the second 
signal is comprised of two palmitoylated cysteines upstream of the CAAX motif, whereas in 
K-Ras4B and Rac1, it is comprised of polybasic-rich sequences.  Rheb1 and Rheb2 lack 
either of these, which may account for the absence of any plasma membrane-associated 
Rheb.  However, other unidentified sequence elements may provide a second signal (187), so 
it remains possible that Rheb subcellular localization is not dictated solely by CAAX-
signaled modifications.   
FTase inhibitors (FTIs) are a class of anti-cancer agents that were originally 
developed to inhibit Ras farnesylation and membrane association.  While FTIs have shown 
anti-tumor activity, this activity is not due to inhibition of Ras, but rather to inhibition of 
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other FTase substrates (27, 50), possibly including Rheb (86, 113, 115).  Rce1 and Icmt 
inhibitors, such as cysmethynil, are being developed as potential inhibitors of Ras membrane 
association and function (25, 26), but whether they block Rheb signaling and function is not 
known.  Additionally, farnesyl-containing small molecules, such as S-trans, trans-
farnesylthiosalicylic acid (FTS; salirasib), have been developed as potential inhibitors of Ras 
membrane association and are currently undergoing clinical evaluation (61).  Intriguingly, 
FTS has also exhibited properties of an mTOR inhibitor (77-79), but whether this is due to 
inhibition of farnesylated Rheb is not known. 
In this study, we determined whether inhibition of CAAX-signaled modifications 
could be used to block aberrant Rheb signaling in cancer.  We found that Rheb1 and Rheb2 
both localized to the endoplasmic reticulum (ER) and Golgi apparatus and that the CAAX 
motif of Rheb1, but not of Rheb2, was sufficient for proper localization.  While Rce1- and 
Icmt-catalyzed modifications were required for proper Rheb localization, surprisingly, they 
were dispensable for Rheb-mediated activation of mTOR.  Finally, we found that FTS 
directly blocked mTOR-induced activation of S6K independently of inhibition of Rheb or 
other prenylated proteins, suggesting that FTS is a novel type of mTOR inhibitor. 
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Materials and methods 
Molecular constructs 
pEGFP rat Rheb1 wt, M184L, and C181S and pEGFP human Rheb2 wt, M183L, and 
C180S were generated by polymerase chain reaction (PCR) amplification and ligation into 
the pEGFP-C1 vector.  All primer sequences are available upon request. 
For generation of pEGFP-C3 Rheb C-terminal constructs (Figure 3a), the following 
oligonucleotides were used: 5’-AATTCCCTGCTCGGTGATGTGAG-3’ and 5’-
GATCCTCACATCACCGAGCAGGG-3’ (Rheb1 C4); 5’-
AATTCCCCAAGGCAAGTCTTCATGCTCGGTGATGTGAG-3’ and 5’-
GATCCTCACATCACCGAGCATGAAGACTTGCCTTGGGG-3’ (Rheb1 C9); 5’-
AATTCCCAAAATGGACGGGGCAGCTTCACAAGGCAAGTCTTCATGCTCGGTGAT
GTGAG-3’ and 5’-
GATCCTCACATCACCGAGCATGAAGACTTGCCTTGTGAAGCTGCCCCGTCCATTT
TGGG-3’ (Rheb1 C16); 5’-AATTCCCTGCCATCTCATGTGAG-3’ and 5’-
GATCCTCACATGAGATGGCAGGG-3’ (Rheb2 C4); 5’-
AATTCCCCAAGAGCGTCGCTGCCATCTCATGTGAG-3’ and 5’-
GATCCTCACATGAGATGGCAGCGACGCTCTTGGGG-3’ (Rheb2 C8); 5’-
AATTCCCCGTGTGGAGAATTCCTATGGGCAAGAGCGTCGCTGCCATCTCATGTGA
G-3’ and 5’-
GATCCTCACATGAGATGGCAGCGACGCTCTTGCCCATAGGAATTCTCCACACGG
GG-3’ (Rheb2 C15).  Oligonucleotides were ligated into the EcoRI and BamHI sites of the 
pEGFP-C3 vector and verified by DNA sequencing. 
68
 pcDNA3 HA-K-Ras G12V, pcDNA3 FLAG-Rheb1 N153T, and pcDNA3 AU1-
mTOR E2419K were described previously (174, 188, 189).  pEYFP H-Ras (wild-type) was a 
gift from Dr. Mark Philips (New York University) (190).  pRK7 HA-S6K1 was obtained 
from Addgene (Cambridge, MA) (191). 
 
Cell culture and transfections 
NIH 3T3 mouse fibroblasts were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% calf serum.  COS-7 monkey epithelial cells were 
maintained in DMEM supplemented with 10% fetal calf serum.  Rce1 +/+, Rce1 -/-, Icmt 
+/+, and Icmt -/- mouse embryo fibroblasts (MEFs) were from Dr. Stephen Young 
(University of California at Los Angeles) and were cultured as described previously (192).   
FTI-2153 and GGTI-2417 were obtained from Dr. Saïd Sebti (Moffit Cancer Center) 
and Dr. Andrew Hamilton (Yale University) (193, 194) and  FTS was obtained from Dr. 
Yoel Kloog (Tel Aviv University) (195).  Lovastatin and rapamycin were purchased from 
Sigma-Aldrich (St. Louis, MO). 
Transient transfections were performed in serum-free Opti-MEM using 
Lipofectamine and Plus reagents (Invitrogen, Carlsbad, CA).  For live cell microscopy, the 
medium was replaced with phenol red-free complete growth medium, and cells were imaged 
24 to 48 h following transfection.  When indicated, cells were serum-starved overnight 24 h 
following transfection, and then amino acid-starved for 1 h in phosphate buffered saline 
(PBS) containing magnesium and calcium. 
 
Immunofluorescence and confocal microscopy 
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Live cells were stained with 5 μM BODIPY TR C5 Ceramide (Molecular Probes, 
Carlsbad, CA), 500 nM MitoTracker Red (Molecular Probes), or 75 nM LysoTracker Red 
(Molecular Probes).  
For immunofluorescence, cells were fixed in 4% paraformaldehyde and 
permeabilized with 0.2% Triton X-100 in PBS, blocked in 2% BSA in PBS, and incubated 
with the following primary antibodies: GM130 (BD Biosciences, Bedford, MA), EEA1 (BD 
Biosciences), ERp72 (Calbiochem, La Jolla, CA), or LAMP2 (Developmental Studies 
Hybridoma Bank, University of Iowa, Iowa city, IA), followed by Alexa Fluor 594 goat anti-
mouse antibody or goat anti-rabbit antibody (Molecular Probes).  Images were captured from 
a Zeiss 510 Meta Inverted Laser Scanning Confocal microscope using LSM 510 Meta 
software. 
 
Western blot analysis 
Cells were lysed in buffer containing 1% NP40, 0.25% deoxycholic acid, 10% 
glycerol, 25 mM HEPES, 50 mM NaCl, and 10 mM MgCl2, supplemented with EDTA-free 
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and phosphatase 
inhibitor I and II (Sigma-Aldrich).  Equal amounts of protein were resolved by SDS-PAGE, 
transferred onto Immobilon P membranes (Millipore, Bedford, MA), and immunoblotted 
with primary antibodies: anti-phospho-p70 S6 kinase (Thr389), anti-p70 S6 kinase, anti-
phospho-S6 ribosomal protein (Ser235/236), anti-S6 ribosomal protein, and anti-mTOR (Cell 
Signaling Technology, Danvers, MA); anti-HA.11 (Covance, Berkeley, CA); anti-GFP 
(Clontech, Mountain View, CA); anti-Rheb1 (Millipore); anti-K-Ras (CalBiochem); anti-
Rap1 (Santa Cruz Biotechnology, Santa Cruz, CA);  and anti-β-actin (Sigma-Aldrich). 
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Results 
Rheb1 and Rheb2 localize to the ER and Golgi. 
Previous reports indicated that ectopically expressed Rheb1 localizes to the Golgi 
apparatus (130), endoplasmic reticulum (ER) (114), and vesicular structures (103, 130, 196), 
and that endogenous Rheb localizes to mitochondria (92).  The precise subcellular 
localization of Rheb2 has not been described.  Therefore, we first wanted to confirm and 
extend the previous disparate observations on Rheb1 and additionally to evaluation Rheb2 
localization. 
Because no Rheb2 antibody was available for evaluation of endogenous protein, we 
utilized green fluorescent protein (GFP)-tagged Rheb proteins for our analyses.  Previous 
studies with similar GFP-tagged Ras family small GTPases have validated this approach for 
accurate determination of endogenous protein subcellular distribution (197-199).  We 
transiently transfected COS-7 epithelial cells with either GFP alone or with GFP-tagged 
Rheb1 and Rheb2 and treated live cells with BODIPY TR C5 ceramide, which detects cis- 
and trans-Golgi and associated vesicles, as well as with MitoTracker, a mitochondrial 
marker, and LysoTracker, a lysosome marker.  In addition, we fixed cells and stained with 
markers of the following intracellular compartments: ERp72 (ER), GM130 (cis-Golgi), 
EEA1 (early endosomes), and LAMP2 (late endosomes). GFP-Rheb1 and GFP-Rheb2 both 
exhibited strong colocalization with BODIPY TR C5-ceramide (live cells) and GM130 (fixed 
cells), confirming that they localize to the Golgi apparatus (Figures 3-1A and 3-1B).  We also 
observed colocalization with ERp72, indicating ER localization (Figure 3-1C).  We did not 
observe colocalization of either Rheb1 or Rheb2 with EEA1, LAMP2, LysoTracker, or 
MitoTracker, suggesting that Rheb1 and Rheb2 do not localize to early endosomes, late 
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Figure 3-1. Rheb1 and Rheb2 are localized primarily to the ER and Golgi.  COS-7 cells were 
transiently transfected with pEGFP vector or with pEGFP encoding GFP-tagged Rheb1 or Rheb2.  
(A) Rheb localization in cis- and trans-Golgi and associated endomembranes. Live cells were 
imaged after staining with BODIPY TR C5 ceramide.  (B) Rheb localization in cis-Golgi.  Cells 
were fixed and immunostained with mouse anti-GM130 antibody followed by Alexa Fluor 594-
conjugated anti-mouse secondary antibody.  (C) Rheb localization in the ER.  Cells were fixed and 
immunostained with rabbit anti-ERp72 antibody followed by Alexa Fluor 594-conjugated anti-rabbit 
secondary antibody.  All images were acquired on a Zeiss confocal microscope using LSM 
software.  Data shown are representative of more than 10 images from at least two independent 
experiments.
A. B.
C.
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endosomes, lysosomes, or mitochondria.  We confirmed these results in NIH 3T3 mouse 
fibroblasts (data not shown) and we observed similar localization of GFP-Rheb in fixed and 
live cells. 
 
The CAAX motif of Rheb1, but not Rheb2, is sufficient for proper localization. 
Next, we determined the minimal C-terminal amino acid sequences sufficient for 
proper Rheb localization.  Since Rheb proteins lack either a cysteine or a polybasic amino 
acid-rich stretch upstream of their CAAX motifs (Figure 3-2A), we hypothesized that they 
lack a “second signal” for localization and that the CAAX motif alone would dictate proper 
subcellular localization.  To address this possibility, we engineered expression constructs 
encoding the last 4 amino acids of either Rheb1 (CSVM; Rheb1 C4) or Rheb2 (CHLM; 
Rheb2 C4) fused to GFP (Figure 3-2B).  We also created similar constructs with 
progressively longer C-terminal Rheb sequences to determine the minimum membrane 
targeting sequence of Rheb and transiently transfected them into NIH 3T3 cells.  As controls, 
we used GFP-tagged full-length (FL) Rheb1 and Rheb2, as well as GFP-tagged Rheb1 
C181S and Rheb2 C180S (“SAAX” mutants), which cannot be farnesylated, and hence 
display a nuclear and cytoplasmic localization identical to GFP alone (Figure 3-2C).  Rheb1 
C4, C9, and C16 all exhibited a subcellular localization indistinguishable from that of full 
length Rheb1, suggesting that the CAAX motif-signaled modifications alone are sufficient 
for proper Rheb1 localization (Figure 3-2C).  Surprisingly, Rheb2 C4 did not localize to the 
distinct perinuclear region as seen with full length Rheb2, but instead exhibited a more 
diffuse cytoplasmic localization, and indicating that it was partially mislocalized, but still 
distinct from the localization of the unfarnesylated SAAX mutant.  In contrast, Rheb2 C8 
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Figure 3-2. CAAX-signaled modifications alone are sufficient for Rheb1 but not Rheb2 
subcellular localization to the ER and Golgi. (A) Comparison of C-terminal membrane 
targeting sequence elements of H-Ras, K-Ras4B, Rnd3, Rheb1, and Rheb2.  Palmitoylated
cysteines (in H-Ras) and polybasic residues (in K-Ras 4B and Rnd3) are underlined.  The C-
terminal CAAX motifs are shaded.  (B) GFP fusion proteins terminating in the Rheb1 or Rheb2 C-
terminal sequences shown were encoded by cDNA sequences subcloned into the pEGFP vector.  
(C) NIH 3T3 cells were transiently transfected with pEGFP vector, or with pEGFP encoding the 
following proteins: GFP-tagged full-length Rheb1 C181S (Rheb1 SAAX), full-length Rheb2 C180S 
(Rheb2 SAAX), the indicated C-terminal Rheb1 or Rheb2 sequences, or full-length (FL) Rheb1 or 
Rheb2.  Live cells were imaged by confocal microscopy.  Data shown are representative of two 
independent experiments.
A.
B.
C.
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displayed a localization identical to the full length protein, suggesting that amino acid 
residues immediately upstream of the CAAX motif are required for proper Rheb2 
localization to the Golgi.   
 
Localization of farnesylated Rheb is more dependent on Rce1- and Icmt-catalyzed 
modifications than geranylgeranylated Rheb. 
A previous study showed that Rheb1 localization is impaired in MEFs lacking Rce1 
or Icmt, but whether Rheb1 function was impaired in these MEFs was not addressed (186).  
To determine if Rheb1-mediated activation of mTORC1 was dependent on these 
modifications, we first sought to confirm these localization findings, and to extend them to 
Rheb2.  We transiently transfected wild-type (Rce1 +/+ and Icmt +/+), Rce1-deficient (Rce1 
-/-), and Icmt-deficient (Icmt -/-) MEFs with expression vectors encoding GFP-Rheb1 and 
GFP-Rheb2.  Consistent with previous results for Rheb1 (186), we found that the normal 
localization of both Rheb1 and Rheb2 was completely impaired in Icmt -/- MEFs.  Both 
Rheb1 and Rheb2 showed significant nuclear accumulation and were indistinguishable from 
the subcellular distribution of GFP alone (Figures 3-3A and 3-3B).  Rce1 deficiency is 
expected to prevent the subsequent Icmt modification.  However, Rheb1 and Rheb2 were 
only partially mislocalized in Rce1 -/- MEFs: Rheb1 and Rheb2 accumulated in the nucleus 
and cytosol, but Golgi localization was still visible (Figures 3-3A and 3-3B).  Thus, Rheb1 
and Rheb2 are more dependent on Icmt-mediated methylation than on Rce1-mediated AAX 
cleavage, a pattern that we have observed with other farnesylated small GTPases (192). 
The CAAX motifs of some GTPases, particularly Rho GTPases, are substrates for 
geranylgeranyltransferase-I (GGTase-I)-catalyzed addition of a longer C20 geranylgeranyl 
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Figure 3-3A. Rheb subcellular localization is dependent on Rce1- and Icmt-catalyzed 
modifications. Rce1 +/+, Rce1 -/-, Icmt +/+, and Icmt -/- MEFs were transiently transfected with 
pEGFP vector or with pEGFP encoding GFP-tagged Rheb1 (F-Rheb1), Rheb1 M184L (GG-
Rheb1), Rheb2 (F-Rheb2), or Rheb2 M183L (GG-Rheb2).  Live cells were imaged by confocal
microscopy.  Data shown are representative of three independent experiments.
76
co
m
pl
et
el
y 
m
is
lo
ca
liz
ed
pa
rt
ia
lly
 m
is
lo
ca
liz
ed
pr
op
er
ly
 lo
ca
liz
ed
Ic
m
t+
/+
0%20
%
40
%
60
%
80
%
10
0%
F-
R
he
b1
G
G
-R
he
b1
F-
R
he
b2
G
G
-R
he
b2
Percent of cells
0%20
%
40
%
60
%
80
%
10
0%
F-
R
he
b1
G
G
-R
he
b1
F-
R
he
b2
G
G
-R
he
b2
Ic
m
t-
/-
0%20
%
40
%
60
%
80
%
10
0%
F-
R
he
b1
G
G
-R
he
b1
F-
R
he
b2
G
G
-R
he
b2
0%20
%
40
%
60
%
80
%
10
0%
F-
R
he
b1
G
G
-R
he
b1
F-
R
he
b2
G
G
-R
he
b2
Percent of cells
R
ce
1 
+/
+
R
ce
1 
-/-
B
.
Fi
gu
re
 3
-3
B
.
R
he
b 
su
bc
el
lu
la
r
lo
ca
liz
at
io
n 
is
 d
ep
en
de
nt
 o
n 
R
ce
1-
an
d 
Ic
m
t-c
at
al
yz
ed
 m
od
ifi
ca
tio
ns
.Q
ua
nt
ifi
ca
tio
n 
of
 th
e 
da
ta
 s
ho
w
n 
in
 
(A
). 
 A
t l
ea
st
 3
0 
ce
lls
 in
 e
ac
h 
co
nd
iti
on
 w
er
e 
sc
or
ed
..
77
isoprenoid lipid.  A previous study found that the localization of geranylgeranylated proteins 
is less dependent on Rce1- and Icmt-catalyzed modifications than farnesylated protein 
localization (200).  Whether modification by the more hydrophobic geranylgeranyl group 
also reduces Rheb sensitivity to Icmt and Rce1 loss was not known.  To obtain 
geranylgeranylated Rheb (GG-Rheb) mutants, we mutated the C-terminal amino acid of 
Rheb1 and Rheb2 from methionine to leucine (Rheb1 M184L and Rheb2 M183L).  Similar 
CAAX mutants of S. pombe and human Rheb showed FTase-independent function (113, 115, 
131, 201).  We utilized pharmacologic inhibitors of FTase and GGTase-I (GGTI) and 
confirmed that GG-Rheb was less sensitive to inhibition by FTI than wild-type farnesylated 
Rheb (F-Rheb; data not shown).   
 To determine whether localization of GG-Rheb also depends on Rce1- and Icmt-
catalyzed modifications, we transiently transfected wild-type, Rce1 -/-, and Icmt -/- MEFs 
with GFP-tagged GG-Rheb1 and GG-Rheb2.  As expected, in wild-type MEFs, GG-Rheb2 
displayed identical subcellular localization to F-Rheb. However, we were surprised to find 
that GG-Rheb1 localization was similar to that seen with wild type F-Rheb1 in only a subset 
of cells.  Instead, a majority (74-77%) of GG-Rheb1 expressing cells showed partially (48-
66%) or completely (11-26%) mislocalized distributions (Figures 3-3A and 3-3B).  Thus, 
unlike most Ras and Rho small GTPases, where the type of isoprenoid modification did not 
alter protein localization, geranylgeranyl modification did not substitute for farnesylation to 
fully support Rheb1 subcellular localization. 
In Rce1 -/- MEFs, F-Rheb1 and GG-Rheb1 were partially mislocalized (74-76%) 
(Figure 3-3B).  However, when expressed in Icmt -/-  MEFs, a much lower percentage (48%) 
of GG-Rheb1 was completely mislocalized when compared to F-Rheb1 (95%).  Similarly, a 
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majority of GG-Rheb2 (>50%) retained proper localization in both Rce1 -/- and Icmt -/- cells, 
although all of the F-Rheb2 was partially or completely mislocalized in these cells.  Thus, 
modification by a geranylgeranyl group reduces the requirement of both Rheb1 and Rheb2 
for the subsequent CAAX modifications, particularly by Icmt. 
 
Rheb activation of mTOR is more dependent on farnesylation than on postprenylation CAAX 
processing. 
Since Rheb1 and Rheb2 are mislocalized in the absence of Rce1 and Icmt, we asked 
if Rheb signaling was impaired in Rce1 -/- and Icmt -/- MEFs.  First, we wanted to confirm in 
our assays that Rheb activation of mTOR is dependent on farnesylation (130).  We 
transfected wild-type or knockout MEFs with constructs encoding GFP-tagged fusion 
proteins of an activated mutant of Rheb1 (Q64L) with an intact CAAX sequence or with two 
CAAX missense mutants: a geranylgeranylated variant (X=L; M184L), designated GG-
Rheb1, and a nonfarnesylated mutant (X=S; M184S), designated Rheb1-SAAX.  As 
expected, both F-Rheb and GG-Rheb efficiently induced S6K phosphorylation in wild-type 
MEFs (Figure 3-4A).  In agreement with previous observations (107, 115, 130), we found 
that the nonfarnesylated Rheb1-SAAX mutant was greatly impaired in stimulating S6K 
phosphorylation.   
Since Rheb1-SAAX fails to undergo all three CAAX-signaled modifications, we next 
determined a role for the Rce1- and Icmt-catalyzed modifications in Rheb1 function.  
Surprisingly, both F-Rheb and GG-Rheb retained the ability to stimulate S6K 
phosphorylation when expressed in either Rce1 -/- or Icmt -/- MEFs (Figure 3-4A).   
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Figure 3-4.  Rce1- and Icmt-catalyzed modifications are not required for Rheb1 activation of
S6K. (A) Wild-type (Icmt +/+) Rce1 -/-, and Icmt -/- mouse embryo fibroblasts were transiently 
transfected with pEGFP vector or with pEGFP encoding Rheb1 Q64L (F-Rheb1 64L), Rheb1 
M184L/Q64L (GG-Rheb1 64L), or Rheb1 C181S/Q64L (Rheb1-SAAX 64L), along with pRK7 HA-
S6K1, and serum- and amino-acid starved as described in Materials & Methods.  Cell lysates were 
resolved by SDS-PAGE and immunoblotted with antibodies to phospho-S6K, HA, GFP, or β-actin
(loading control).  (B) Wild-type (Icmt +/+), Rce1 -/-, and Icmt -/- MEFs were transiently transfected
with pcDNA3 vector, or with pcDNA3 encoding HA-tagged K-Ras G12V, FLAG-tagged Rheb1 
N153T, or AU1-tagged mTOR E2419K, along with pRK7 HA-tagged S6K1, and serum- and amino 
acid-starved as in (A).  Cell lysates were resolved by SDS-PAGE and immunoblotted with 
antibodies to phospho-S6K, HA, Rheb1, K-Ras, or β-actin (loading control).  Data shown are 
representative of at least two independent experiments.
A.
B.
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Since these observations were unexpected, we also compared the activity of Rheb1 
with a different N-terminal tag (FLAG) and activating mutation (N153T) (188) with that of 
constitutively activated K-Ras4B(G12V), which is expected to require these modifications, 
and with that of constitutively activated mTOR (E2419K; a kinase-domain mutation) (189), 
which is not a substrate for either CAAX modifying enzyme.  We transiently transfected 
wild-type, Rce1 -/-, and Icmt -/- MEFs with either pcDNA3 empty vector, or with pcDNA3 
encoding constitutively activate mutants of K-Ras (HA-K-Ras G12V), Rheb1 (FLAG-Rheb 
N153T), or mTOR (AU1-mTOR E2419K), along with pRK7 HA-S6K1, and used western 
blot analysis to determine S6K phosphorylation.  Consistent with previous studies (188, 189, 
202), we observed that activated K-Ras4B, Rheb1, and mTOR all efficiently induced 
phosphorylation of S6K in wild type MEFs.  As expected, since mTOR is not a substrate for 
Rce1 and Icmt, constitutively active mTOR also induced S6K phosphorylation in Rce1 -/- 
and Icmt -/- cells (Figure 3-4B).  Unexpectedly, K-Ras4B also did not show impaired S6K 
phosphorylation when expressed in Rce1 -/- or Icmt -/- MEFs.  However, this result is 
consistent with our recent observation that K-Ras4B subcellular localization and plasma 
membrane association were not impaired to any significant degree in Rce1- or Icmt-null cells 
(192). Consistent with GFP-tagged Rheb1, FLAG-tagged Rheb-induced S6K 
phosphorylation was also not impaired in Rce1 -/- or Icmt -/- MEFs.  Thus, while these 
CAAX modifications are necessary for proper subcellular localization, Rheb activation of 
mTOR is not impaired in the absence of Rce1 or Icmt function.  Taken together, these data 
suggest that Rheb activation of mTOR is more dependent on farnesylation than on Rce1- and 
Icmt-catalyzed modifications. 
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FTS does not disrupt the subcellular localization of Rheb. 
FTS (also called salirasib) is a farnesylcysteine mimetic that is proposed to dislodge 
Ras proteins from the plasma membrane and thus inhibit Ras activity (61, 203).  However, 
whether FTS also displaces and inhibits the function of other farnesylated proteins, such as 
Rheb, is not known.  FTS has also been shown to reduce phosphorylation of the mTOR 
substrates S6K and 4E-BP1 (77, 78), but whether this is due to Rheb inhibition was not 
investigated.  To determine if FTS inhibits Rheb localization, we transiently expressed GFP-
tagged Rheb1 or YFP-tagged H-Ras in NIH 3T3 cells and treated them with FTS.  As a 
control, we treated cells with FTI-2153, since FTIs are known to impair Rheb and H-Ras 
localization (130, 186, 192).  Indeed, GFP-Rheb and YFP-H-Ras were completely 
mislocalized in FTI-treated cells (Figure 3-5).  Surprisingly, FTS did not cause 
mislocalization of either H-Ras or Rheb.  These results suggest that FTS does not detectably 
disrupt the membrane association and subcellular localization of Rheb or Ras proteins under 
these conditions. 
 
FTS inhibits mTOR-induced S6K activation and reduces mTOR protein levels. 
Since it remained possible that FTS may disrupt Rheb interaction with mTOR, we 
next asked if FTS inhibits Rheb-induced activation of mTOR.  Activated K-Ras4B, Rheb1, 
and mTOR all efficiently induced S6K phosphorylation in vehicle (DMSO)-treated cells 
(Figure 3-6A).  As expected, FTI treatment strongly inhibited Rheb1-induced S6K 
phosphorylation and resulted in a shift in Rheb mobility as seen by SDS-PAGE, indicating 
the accumulation of unprenylated Rheb1.  We also observed an increase in Rheb protein 
levels in FTI-treated cells, in agreement with previous studies (130).  Importantly, FTI 
82
Figure 3-5.  FTS does not disrupt Rheb or H-Ras subcellular localization.  NIH 3T3 cells were 
transiently transfected with pEGFP vector, pEGFP encoding GFP-tagged Rheb1, or pEYFP
encoding YFP-tagged H-Ras and treated with DMSO (Vehicle), 5 μM FTI-2153, or 75 μM FTS 
overnight.  Live cells were imaged by confocal microscopy. 
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treatment did not block mTOR-induced S6K phosphorylation, since mTOR E2419K is 
constitutively active and is not dependent on Rheb.  In contrast, FTS strongly inhibited K-
Ras, Rheb, and mTOR-induced S6K phosphorylation, suggesting that FTS inhibits S6K 
activation at the level of mTOR, and not by inhibiting upstream activators.   
Surprisingly, we found that FTS treatment of NIH 3T3 cells decreased levels of both 
endogenous and ectopically expressed mTOR protein (Figure 3-6A), but did not decrease 
levels of K-Ras, Rheb, or β-actin.  Thus, FTS inhibition of mTOR may be due, in part, to 
promoting the loss of mTOR protein.  However, FTS treatment did not decrease endogenous 
mTOR in MCF-7 human breast carcinoma cells, whereas it did decrease phospho-S6K in 
these cells (Figure 3-7, discussed below), suggesting that the FTS-induced reduction in 
mTOR levels is not the primary cause of the reduction in S6K phosphorylation. 
 
FTS inhibition of mTOR does not require protein prenylation. 
One explanation for the above results could be that FTS is blocking the function of an 
unidentified prenylated protein required for mTOR-induced S6K phosphorylation.  For 
example, Cdc42 and Rac1, which are geranylgeranylated, have previously been implicated in 
S6K phosphorylation (204).  In addition, RalA, another geranylgeranylated protein, was 
recently shown to be required for Rheb-induced S6K phosphorylation (106).  To determine 
whether prenylated proteins are required for mTOR-induced S6K phosphorylation, we 
transiently transfected NIH 3T3 cells as described above, and treated cells with FTI, a 
GGTase-I inhibitor (GGTI), or both.  We verified that the GGTI was functional and inhibited 
modification of Rap1A (Figure 3-6B).  As expected, FTI inhibited Rheb1-induced, but not 
mTOR-induced, S6K phosphorylation (Figure 3-6B).  Combined treatment with FTI and 
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GGTI efficiently inhibited K-Ras4B-induced S6K phosphorylation, presumably as a 
consequence of blocking alternative prenylation of K-Ras4B (205, 206).  In contrast, FTI and 
GGTI in combination failed to prevent mTOR-induced S6K phosphorylation, suggesting that 
prenylated proteins modified by either farnesyltransferase or GGTase-I are not required for 
mTOR activation of S6K. 
 To confirm these results and to exclude the possibility that prenylated GGTase-II 
substrates (such as Rab GTPases) are required for mTOR activation of S6K, we treated cells 
with lovastatin, which blocks all protein prenylation.  As expected, lovastatin treatment 
caused a mobility shift in Rheb, and reduced both Rheb- and K-Ras-induced S6K 
phosphorylation (Figure 3-6C).  However, lovastatin failed to inhibit mTOR-induced S6K 
phosphorylation.  Thus, FTS inhibition of mTOR does not involve inhibition of a prenylated 
protein. 
 
FTS inhibits endogenous S6K activity in breast cancer cells. 
As described previously (77), we confirmed that FTS inhibited endogenous S6K 
activity in MCF-7 cells, but treatment did not affect mTOR or Rheb1 protein levels (Figure 
3-7).  These data are consistent with the hypothesis that FTS is an mTOR inhibitor.   
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Figure 3-7. FTS blocks endogenous S6K activation in MCF-7 cells. MCF-7 cells growing in 
complete medium were treated with 100 μM FTS in complete medium for 0, 2, 6, 16, or 24 h.  Cell 
lysates were resolved by SDS-PAGE and immunoblotted with antibodies to phospho-S6K (pS6K), 
total S6K, phospho-S6 (pS6), total S6, mTOR, and β-actin (loading control).  Data shown are 
representative of two independent experiments.
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Discussion 
Rheb functions as a key intermediate in the PI3K-AKT-TSC-Rheb-mTOR network 
that is aberrantly activated in a majority of human cancers (122).  While pharmacologic 
inhibitors of PI3K, AKT and mTOR are currently in Phase I/II clinical trials, Rheb may also 
be a useful target.  A key goal of our study was to determine if specific approaches can block 
Rheb function by disrupting the membrane association and subcellular distribution of Rheb 
essential for its biological activity.  We assessed two different strategies for blocking Rheb 
function.  The first strategy involves preventing the CAAX-mediated posttranslational 
modifications that promote Rheb membrane association.  We found that both Rheb1 and 
Rheb2 localization, but not mTOR activation, was disrupted in the absence of the post-
prenylation processing enzymes Rce1 or Icmt, suggesting that inhibitors of these enzymes 
will not block Rheb signaling and oncogenic activity.  The second strategy involves 
inhibition of Rheb endomembrane association by FTS.  Unexpectedly, we found that FTS did 
not effectively impair Rheb or Ras protein membrane association.  Instead, we found that 
FTS blocked Rheb activation of mTOR, but this effect was independent of inhibition of Rheb 
or of any other prenylated protein.  Rather, we suggest that a potent mechanism for FTS-
mediated growth inhibition may involve direct inhibition of mTOR. 
 Although the subcellular localization of Rheb proteins has been addressed in multiple 
previous studies, conflicting observations were made (92, 103, 114, 130, 186).  Furthermore, 
the precise subcellular localization of Rheb2 had not been determined.  We confirmed that 
Rheb1 is primarily localized to the Golgi and ER endomembranes, in agreement with others 
(114, 130).  We also found that the localization of Rheb2 is indistinguishable from that of 
Rheb1, and that Rheb localization overlaps with the observed localization of Rheb binding 
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partners (207-209).  The essentially identical subcellular localization of Rheb1 and Rheb2 
contrasts with the situation seen with closely related isoforms of other Ras family small 
GTPases.  For example, although RalA and RalB share 82% overall sequence identity, their 
distinct subcellular distributions result in strikingly distinct biological roles (158).    
We found that, unlike most Ras and Rho small GTPases, the CAAX motif alone of 
Rheb1 was sufficient for proper localization.  These data are consistent with Choy et al., who 
showed that the CAAX motif of K-Ras and N-Ras alone promoted localization to the ER and 
Golgi (197).  In contrast, the CAAX motif alone was not sufficient for proper localization of 
Rheb2, which required amino acids immediately upstream of the CAAX motif, suggesting 
that the targeting motifs of Rheb1 and Rheb2 are not functionally identical. 
 We also found that geranylgeranylated mutants of Rheb1 and Rheb2 (Rheb1 M184L 
and Rheb2 M183L), like their farnesylated wild-type counterparts, localized to the ER and 
Golgi.  However, the localization of GG-Rheb was less dependent on Icmt- and Rce-1 
catalyzed modifications, in agreement with previous studies showing that the localization of 
geranygeranylated Ras mutants was less dependent on these modifications than farnesylated 
Ras (200).   
Farnesylation of Rheb was required for its ability to activate mTOR, as shown by the 
inability of the nonfarnesylated SAAX mutant of Rheb1 to induce S6K phosphorylation.  
These observations are consistent with several studies showing that FTI impairs S6K or S6 
phosphorylation (113, 115, 131, 210).  In contrast, neither of the post-prenyl processing steps 
was required for Rheb-induced mTOR activation, which was not disrupted in either Rce1 -/- 
or Icmt -/- MEFs.  In addition, we found that the Icmt inhibitor cysmethynil did not block 
Rheb activation of mTOR (data not shown).  These data are consistent with those of Buerger 
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et al., who showed that the methyltransferase inhibitor AFC does not block Rheb-induced 
S6K activation (130).  Therefore, we suggest that inhibitors of Rce1 and Icmt will not inhibit 
Rheb activity. 
 We found that FTS strongly inhibited both Rheb- and mTOR-induced S6K activation.  
FTS is proposed to compete with farnesylated Ras for membrane binding sites and dislodge 
Ras from the membrane, thereby disrupting its function (62, 65, 73, 195).  However, we 
failed to observe detectable disruption of H-Ras or Rheb membrane association.  Instead, our 
data strongly suggest that the FTS-mediated inhibition of mTOR-induced S6K activation is 
not due to inhibition of a prenylated protein.  Rather, our data are consistent with the 
observation that FTS disrupts the association of mTOR with raptor (79).  We failed to 
observe a concomitant decrease in Akt phosphorylation on S473 in FTS-treated cells (Figure 
4-4), suggesting that FTS inhibits mTORC1 but not mTOR complex 2 (mTORC2) activity. 
In summary, we have found that inhibition of Rce1- and Icmt-catalyzed modifications 
does not prevent Rheb activation of mTOR, and that FTS inhibits mTOR through a 
mechanism that does not involve Rheb inhibition. Although FTS is not a direct Rheb 
inhibitor, mTOR is essential for Rheb oncogenic activity (113, 114); hence, FTS would be 
expected to disrupt both Rheb- and mTOR-induced transformation.  Since FTS is currently in 
clinical trials for cancer treatment, our results have significant implications for the selection 
of who that may benefit from FTS therapy and suggest that S6K phosphorylation may be a 
useful biomarker to monitor FTS activity.   
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CHAPTER 4 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
 Aberrant Ras signaling drives the growth and progression of many cancers.  Although 
Ras mutations are rare in breast cancers, other related Ras family members may be 
deregulated in breast cancer and may contribute to breast cancer progression.  I have chosen 
to focus on the roles of two estrogen-regulated Ras family small GTPases in breast cancer.  
The majority of breast cancers depend on estrogen for growth, and hence proteins regulated 
by estrogen may represent attractive therapeutic targets for the treatment of breast cancer.  
The primary aims of my studies were to define the roles of Rerg and Rheb in breast cancer 
progression.  Unexpectedly, I found that loss of Rerg expression did not significantly 
contribute to breast cancer progression.  While I was unable to further examine the role of 
Rheb in breast cancer due to technical limitations, my studies did identify strategies to block 
Rheb-mTOR signaling that may be therapeutically beneficial for patients with breast and 
other cancers.  My studies have also laid a foundation for future studies of Rerg and Rheb 
function in normal cells and in tumorigenesis. 
 
Is Rerg a growth inhibitor?  Previous studies have implicated Rerg as a growth 
inhibitor in ERα-positive MCF-7 breast cancer cells (151).  In Chapter 2, I further 
investigated the effects of Rerg expression on breast cancer cell growth and invasion.  
However, I failed to observe a difference in the growth of these cells in vitro upon depletion 
of Rerg expression by shRNA.  Furthermore, a tamoxifen-inducible ER-Rerg fusion protein 
did not reduce the aggressiveness of ERα-negative breast cancer cells in vitro.  What 
accounts for these discrepancies?  First, the growth inhibitory properties of Rerg may depend 
on cell context.  It is possible that high expression of Rerg may restrain the growth of ERα-
positive breast cancers, but may not function the same way in ERα-negative breast cancer 
cells.  Indeed, high Rerg expression correlated with favorable outcome in ERα-positive 
breast cancer patients (Perou and colleagues, unpublished observations).  Secondly, either my 
results or the previous studies may have been compromised by nonphysiologic experimental 
conditions.  In the previous study, the growth inhibition observed upon transfection with 
Rerg may be the result of ectopic Rerg expression at higher than physiological levels.  
Conversely, in my studies, insufficient knockdown levels may have prevented an accurate 
assessment of the effects of loss of Rerg expression in ERα-positive breast cancer cells.  
Other lentiviral shRNAs targeting Rerg should be tested for a more complete knockdown of 
Rerg expression and may lead to more pronounced differences in the growth or invasive 
properties of ERα-positive breast cancer cells.  It is also possible that the fusion of the ERα 
ligand binding domain to Rerg disrupted Rerg activity, as discussed in chapter 2.  Thus, 
creation of a doxycycline-inducible Rerg expression system would circumvent this caveat; it 
will be important to test whether induction of untagged Rerg decreases the growth of breast 
cancer cells.  Finally, it remains possible that Rerg may have a more pronounced role in 
breast cancer growth in vivo. 
Although in vitro soft agar formation strongly correlates with tumorigenic potential in vivo, 
there are instances of proteins with no apparent effect on soft agar assays, yet these proteins 
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do affect xenograft growth or metastasis in vivo.  As I have only studied the effects of 
manipulating Rerg expression in vitro, my studies do not rule out a possibility that Rerg is 
involved in tumor formation or metastasis in vivo.  For example, Rerg may play a role in the 
tumor microenvironment: it may mediate tumor/stromal interactions, immune response, 
angiogenesis, etc.  Therefore, it will be important to test whether knocking down or restoring 
Rerg expression enhances or reduces orthotopic tumor xenograft growth (by injecting tumor 
cells containing Rerg shRNA or ER-Rerg into the mammary fat pad) or affects the formation 
of metastases in the lung (by injecting tumor cells into the tail veins of SCID mice). 
 The generation of a Rerg knockout mouse will also shed considerable light on 
whether Rerg is involved in breast cancer initiation or progression.  First, it will be important 
to determine if Rerg is expressed in current transgenic mouse models of breast cancer, such 
as the mouse mammary tumor virus (MMTV)-HER2 model.  If so, then crossing this model 
with a Rerg knockout mouse will determine if Rerg loss enhances tumor growth and 
metastasis.  If the current mouse models of breast cancer do not express Rerg, then a 
transgenic mouse expressing Rerg under a mammary-specific promoter should be crossed to 
these mice to determine if Rerg expression reduces tumor growth or metastasis.  Assuming 
that deleting the Rerg gene does not result in embryonic lethality, it will also be interesting to 
determine if mice lacking Rerg exhibit increased tumor incidence, suggesting that Rerg may 
suppress the formation of tumors. 
 
What is the role of Rerg in normal cells and in development?  Rerg mRNA is 
expressed in many tissues, including heart, skeletal muscle, kidney, and ovary (153), 
suggesting that it may play an important role in a variety of normal cellular processes.  
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Several approaches can be used to identify the function of Rerg in normal cells and in 
mammalian development.  First, the identification of Rerg binding partners and effectors will 
shed considerable light on the signaling pathways and cellular processes in which Rerg 
participates.  Although yeast 2-hybrid screens have not been successful in identifying Rerg 
binding partners, other approaches may be used.  One potential method would be to express 
GFP-tagged Rerg in cells, immunoprecipitate Rerg using an anti-GFP antibody, and separate 
interacting proteins by SDS-PAGE.  Bands may then be removed and proteins identified by 
mass spectrometry analysis (211, 212).  This proteomic approach has the advantage over the 
yeast 2-hybrid method because it allows expression and post-translational modifications to 
occur in mammalian cells and allows for the precipitation of multi-protein complexes to 
detect indirect interactions.  Our laboratory has successfully used this approach to identify 
binding partners of other small GTPases, such as RhoBTB2 and RhoBTB3 (unpublished 
observations).  To identify specific effectors of Rerg, this approach may be modified by 
expressing the GFP-tagged Rerg Q64L mutant, which exhibits increased GTP binding (151), 
along with GFP-Rerg S20N, predicted to be bound to GDP (153).  Proteins that preferentially 
associate with Rerg Q64L and require an intact effector domain would be predicted to be 
bona fide Rerg effectors.  This approach could also be performed in Rerg-positive cancer cell 
lines in order to identify effector proteins that may mediate the putative growth inhibitory 
properties of Rerg.  Interacting proteins should be validated by co-immunopredicipation 
using antibodies to endogenous proteins. 
Secondly, determining the genes that are regulated in response to Rerg expression 
may also give clues to the function of Rerg.  The Rerg shRNA I generated may be used to 
reduce Rerg expression in cells that normally express high levels of Rerg.  Next, microarrays 
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may be used to determine which genes are up- or down-regulated in response to Rerg 
repression.  Gene ontology programs may then be used to determine enrichment for groups 
of genes involved in specific cellular processes.  It is likely that Rerg would play a role in 
these processes. 
 A third, and perhaps the most direct, approach to elucidate the function of Rerg is, 
again, the generation of a Rerg knockout mouse.  Rerg-deficient mice should be studied for 
apparent defects in development, immune regulation, etc.  It is possible that Rerg deficiency 
will result in embryonic lethality, in which case it will be interesting to determine the 
function Rerg plays in embryonic development.  Conversely, it is possible that mice lacking 
Rerg will not exhibit an obvious phenotype in normal development.  However, genetic or 
chemical carcinogen-induced oncogenesis in Rerg-deficient mice may reveal a function that 
occurs only under situations of stress.  Finally, determining Rerg binding partners and Rerg-
regulated genes may provide clues as to how to find a phenotype associated with Rerg loss. 
 
What properties of Rerg are required for its function?  Elucidating the biological 
function of Rerg will lay the groundwork for exciting studies to determine the mechanism by 
which Rerg acts.  Ideally, a cellular assay would be developed in which shRNA-mediated 
knockdown of endogenous Rerg causes a biological phenotype.  Ectopic expression of a 
shRNA-insensitive Rerg cDNA could then be used to rescue this effect and restore normal 
cellular function.  Then, mutants of Rerg could be tested to determine whether specific 
properties of Rerg are required for its function.  One major question is whether the GTP-
bound form of Rerg is the “active” form.  Therefore, the Rerg Q64L or S20N mutants could 
be re-expressed in Rerg shRNA-expressing cells.  I would predict that the GTP-bound Rerg 
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Q64L mutant would rescue the phenotype, whereas the GDP-bound S20N mutant would not.  
As mentioned above, discovering Rerg effectors will be a key breakthrough in elucidating a 
Rerg signaling pathway.  Effector domain mutants of Rerg could then be generated to 
determine which effectors mediate the biological functions of Rerg.  shRNA targeting Rerg 
effectors could then be used to determine if loss of Rerg effectors phenocopies Rerg loss.  
Alternatively, activated versions of Rerg effectors could be used to rescue the phenotype of 
Rerg knockdown cells.  Finally, it will be important to determine whether Rerg localization is 
important for its function.  As mentioned above, Rerg is unique from other Ras family 
proteins and lacks a CAAX motif.  My studies found that GFP-tagged Rerg is targeted to the 
cytoplasm.  The Rerg C-terminus could be replaced with that of Ras: will a membrane-
targeted version of Rerg still function properly?  Clearly, once a validated biological function 
is ascribed to Rerg, this will be an active and exciting field of study.  The tools I developed to 
manipulate and detect Rerg expression will be invaluable in these future studies. 
It will also be interesting to determine the upstream regulators of Rerg GTP/GDP 
cycling.  Rerg has been shown to bind, exchange, and hydrolyze GTP (151); are there GEFs 
and GAPs for Rerg that promote these processes?  In addition, many small GTPases, such as 
Ras and Rheb, are regulated by extracellular growth factors and other signals.  Do 
extracellular signals similarly promote Rerg-GTP, or perhaps inhibit Rerg?  To test this, one 
could serum-starve cells overnight, then stimulate with serum or with other growth factors 
for 15 mins, and use thin layer chromatography to detect Rerg binding to radiolabeled GTP 
(151).  These experiments will establish the cellular context of Rerg signaling. 
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Does loss of Rerg expression contribute to the growth of other types of cancer?  
Although my studies did not find a role for Rerg in the growth of breast cancer cells, it 
remains plausible that loss of Rerg expression promotes growth or metastasis of other types 
of tumors.  According to the oncomine database (www.oncomine.org), Rerg mRNA 
expression is frequently downregulated in breast and other types of tumors as well as in 
metastatic tumors compared to non-metastatic counterparts (170-172).  In order to extend 
these findings, one could use the Rerg antibody for IHC analysis on tissues from metastatic 
and primary tumor samples.  A tissue microarray would be particularly useful in determining 
whether Rerg protein is indeed downregulated in different types of tumors.  If this is found to 
be the case, then the Rerg shRNA and tamoxifen-inducible ER-Rerg fusion protein I 
generated in Chapter 2 will be valuable tools in validating a role for Rerg in suppressing the 
growth or metastatic properties of these tumor cells.  If Rerg is found to be a tumor or 
metastasis suppressor, then a primary goal will be to develop strategies that restore Rerg 
expression in tumors. 
 
Therapeutic reexpression of ARHI or Rerg in breast cancer.  Due to the putative 
roles of ARHI and Rerg as tumor suppressors or growth inhibitors in breast (or perhaps 
other) tumors, therapeutic reexpression of these proteins in tumors that have lost their 
expression may be beneficial.  Although a gene therapy approach to simply restore 
expression may be the most direct strategy, this feat remains difficult to accomplish with 
current technology.  Instead, targeting the epigenetic regulation of ARHI and Rerg may be 
more promising.  Expression of both genes is negatively regulated by HDACs (Figure 4-1).  
The HDAC inhibitor trichostatin A restored expression of ARHI and Rerg in breast cancer 
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Figure 4-1. Epigenetic silencing of ARHI and Rerg and strategies to restore their 
expression. The ARHI gene can be epigenetically silenced by promoter hypermethylation, 
catalyzed by DNMTs, and by HDAC/E2F complexes.  The DNMT inhibitor 5-aza-dC and the HDAC 
inhibitor (HDACi) TSA have been shown to restore ARHI expression in some breast cancer cells.  
TSA can also restore Rerg expression in an ERα-negative cell line.  Other methods to restore Rerg
expression in ERα-negative breast cancers could include strategies to upregulate or to stabilize the 
ERα, such as with Src inhibitors, MEK inhibitors, or DNMT inhibitors.  Adapted from Hanker and 
Der, Handbook of Cell Signaling, in press.
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cells (213, 214).  Several HDAC inhibitors are currently in clinical trials to treat cancer, 
including breast cancer, and the HDAC inhibitor vorinostat (Zolinza®) has been approved by 
the FDA for the treatment of cutaneous T-cell lymphoma (215).  It will be important to 
determine whether these HDAC inhibitors restore expression of ARHI or Rerg in primary 
breast cancers lacking expression of these proteins and whether restoration of ARHI or Rerg 
expression correlates with patient response.   
Many tumor suppressors, including ARHI, are epigenetically silenced by promoter 
hypermethylation (Figure 4-1).  DNA methyltransferases (DNMTs) have thus attracted 
interest as therapeutic targets (216).  The DNMT inhibitor 5-aza-2’-deoxycytidine (5-aza-dC) 
reactivated ARHI expression in breast cancer cells (142, 214).  Another way to restore ARHI 
expression could be E2F inhibitors, since RNA interference-mediated suppression of E2F 
family member expression was shown to increase ARHI expression in SKBR3 breast cancer 
cells (141).  Whether the Rerg promoter is hypermethylated or whether Rerg expression can 
be restored by 5-aza-dC treatment is not known, but 5-aza-dC can restore ERα expression in 
ERα-negative breast cancer cells (217).  It will be important to determine if ERα expression 
is sufficient to restore Rerg expression.  If this is the case, then Rerg expression may also be 
restored by inhibitors of the Src tyrosine kinase or MEK1/2 dual specificity kinases, which 
have been shown to increase ERα levels in breast cancer cells (218, 219).  If Rerg or ARHI 
are found to be upregulated by HDAC or other inhibitors, then it will be important to 
determine whether the anti-tumor effects of these pharmacologic agents may be due to 
restoring expression of these GTPases.  To test this, shRNA targeting Rerg or ARHI could be 
used to prevent upregulation in response to treatment, and then tumor growth may be 
monitored.  Since many of these therapies are in preclinical or clinical studies, understanding 
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the effects of ARHI or Rerg re-expression in breast cancer may help to predict patient 
response to these therapies.  
 
Which tumors are dependent on Rheb activity?  Rheb overexpression and 
activation of the Rheb-mTOR pathway have been implicated in many types of cancers, 
including breast cancers, suggesting that Rheb may be a good therapeutic target for these 
cancers.  I initially began work on Rheb in the hopes of defining the role of Rheb in estrogen-
regulated breast cancers.  However, my studies were inconclusive due to technical concerns, 
so I began work on potential strategies to inhibit Rheb function in cancer.  I focused on 
blocking Rheb CAAX-mediated posttranslational processing and localization, mimicking 
similar strategies aimed at blocking oncogenic Ras function in cancer.  My results suggest 
that targeting Rheb post-prenylation processing would not strongly inhibit Rheb function, but 
that the farnesylcysteine mimetic FTS may be more promising in inhibiting Rheb/mTOR 
signaling.  Furthermore, my studies reinforced the concept that farnesylation is strongly 
required for Rheb function, and hence FTIs would be predicted to block Rheb-induced 
oncogenesis, in agreement with previous studies (113, 115).  As more Rheb inhibitors are 
identified, it will be essential to determine the types of tumors that depend on Rheb signaling 
for growth and survival in order to identify an appropriate patient population in which to test 
inhibitors of Rheb. 
One approach to define Rheb-dependent tumor cells would be to screen panels of 
tumor cell lines for sensitivity to Rheb shRNA.  A high-throughput assay, such as the MTT 
cell viability assay, could be used to measure cell viability in response to knocking down 
Rheb expression.  A similar approach using K-Ras shRNA in K-Ras-mutant cells has 
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successfully identified cell lines “addicted” to mutant K-Ras activity (220).  Alternatively, a 
more accurate measure of tumorigenic potential may be the use of soft agar assays to 
determine cell lines that require Rheb for anchorage-independent growth.  Once sensitive cell 
lines are identified, they should be analyzed for specific oncogenic mutations, such as 
PIK3CA or PTEN mutations, as well as Rheb overexpression, to determine if any of these 
molecular aberrations correlate with sensitivity.  In addition, phosphorylation status of 
mTOR downstream targets, such as S6K and 4E-BP1, should be measured in these cell lines 
to determine if sensitivity to Rheb depletion correlates with phosphorylation status of mTOR 
targets.  Phosphorylation of raptor on Ser 863 (221) and phosphorylation of mTOR on Ser 
1261 (222) have also been suggested to correlate with Rheb activity and therefore should be 
tested.  These studies may identify a molecular biomarker to predict patient response to Rheb 
inhibitors.    
However, there are caveats to this approach.  In my studies, I failed to observe a 
decrease in cell proliferation or anchorage-independent growth in breast cancer cells 
expressing Rheb shRNA (Figure 4-2).  This may be due to the presence of Rheb2, which may 
be functionally redundant with Rheb1.  Therefore, it may be necessary to deplete both Rheb1 
and Rheb2 using shRNA targeting each isoform.  Alternatively, overexpression of TSC2 
would be predicted to block activation of both Rheb1 and Rheb2.  Since I was unable to 
achieve stable expression of TSC2 in breast cancer cell lines, presumably due to its strong 
tumor suppressive activity, an inducible TSC2 expression system may be required. 
An emerging theme of targeted anti-cancer therapy is that targeted therapies will most 
likely work better in combination than as single agents (223).  Thus, future studies should 
determine appropriate combination therapy for Rheb inhibitors.  In breast cancer, one could 
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Figure 4-2. Knocking down Rheb1 expression does not significantly reduce estrogen-
induced MCF-7 cell proliferation or anchorage-independent growth.  (A) MCF-7 cells were 
stably infected with empty pSuper.retro.puro vector, or encoding shRNA targeting green 
fluorescent protein (GFP) or luciferase (negative controls), or Rheb1.  Western blots were probed 
with antibodies to phospho-S6 (pS6), Rheb1, or β-actin (loading control).  (B) MCF-7 stable cell 
lines were seeded at equal numbers in 96-well plates and treated with Vehicle, 1 nM estrogen, or 1 
nM estrogen + 1 μM tamoxifen for 5 days.  Cell viability was measured using the MTT assay.  
Results represent the average of 8 replicate wells; error bars represent standard deviation.  (C) 
MCF-7 stable cells were seeded in triplicate into 0.4% soft agar over a 0.6% bottom layer.  After 27 
days, viable colonies were stained in 2 mg/mL MTT.  ImageJ software was used to quantify 
number of colonies from images of scanned plates.  Results represent the average of triplicate 
plates; error bars represent standard deviation.
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foresee combining Rheb inhibitors with endocrine therapies, such as tamoxifen.  The AKT 
pathway is hyperactivated in tamoxifen-resistant breast cancer cell lines (224) and 
constitutively active AKT has been shown to promote tamoxifen resistance in MCF-7 cells 
(14, 128, 225).  This increased tamoxifen resistance was blocked by rapamycin, and is thus 
dependent on mTOR (128).  Furthermore, Rheb inhibition was shown to increase sensitivity 
to tamoxifen-induced apoptosis (115).  Thus, Rheb may play a role in tamoxifen resistance, 
and Rheb inhibition may delay or reduce development of resistance to endocrine therapies.  
To test this, a constitutively active mutant of Rheb (Rheb N153T) could be stably expressed 
in MCF-7 cells, and tamoxifen sensitivity could be determined using the MTT or soft agar 
assay.  Does activated Rheb, like activated AKT, impart resistance to tamoxifen?  It will also 
be interesting to determine whether Rheb is required for tamoxifen resistance.  Tamoxifen-
resistant MCF-7 cells have been developed by culture in the presence of tamoxifen for six 
months; these cells have overcome tamoxifen-induced growth inhibition (226).  Does 
knocking down Rheb using shRNA delay or prevent the development of tamoxifen resistance 
in these cells?  Experiments addressing these questions will be critical to determine whether 
the combination of Rheb inhibitors with endocrine therapy is a rational strategy for breast 
cancer treatment. 
 
Is Rheb the FTI target responsible for FTI anti-tumor activity?  FTIs have 
exhibited some anti-tumor activity in clinical trials, particularly in breast cancer (54, 133, 
227-229).  However, the clinical development of these agents has been hampered by the 
inability to identify a molecular biomarker to predict response or to define a clear patient 
population that will benefit from these agents (50, 230).  Considerable evidence points to a 
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role for Rheb in mediating the anti-tumor activity of FTIs (27, 231).  First, FTIs were found 
to decrease phosphorylation of S6K and 4E-BP1 in cancer cell lines and mammary tumors of 
transgenic mice (115, 126, 210, 232).  In support of these studies, treatment of melanoma 
cells with the FTI lonafarnib reduced levels of phospho-S6K but not phospho-ERK or 
phospho-AKT (233).  Further evidence of the importance of Rheb in FTI anti-tumor activity 
comes from studies using the FTI-insensitive GG-Rheb variant.  Basso et al. found that GG-
Rheb prevented lonafarnib enhancement of tamoxifen-induced apoptosis in MCF-7 cells 
(115), which are exquisitely sensitive to FTIs (234), but whether GG-Rheb also rescued 
lonafarnib-induced inhibition MCF-7 cell growth was not tested.  More recently, Mavrakis 
and colleagues found that GG-Rheb Q64L promoted FTI resistance in lymphoma cells (113).  
However, in my studies, I failed to observe a change in FTI sensitivity (measured using the 
MTT assay and soft agar assay) when I stably expressed GG-Rheb in MCF-7 cells (Figure 4-
3).  This may be due to low expression levels of GG-Rheb.  Alternatively, GG-modified 
Rheb may not fully recapulate the activities of authentic Rheb.  In addition, I did not use 
activated GG-Rheb, which may have given a stronger phenotype.  I also failed to observe a 
difference in the FTI sensitivity of MCF-7 cells expressing Rheb shRNA.  Again, this may be 
due to expression of Rheb2.  Consistent with my results, a recent clinical trial of the FTI 
tipifarnib in breast cancer found that response to tipifarnib did not correlate with Rheb 
overexpression (229).  However, S6K and 4E-BP1 phosphorylation levels were not 
examined.  Thus, the role of Rheb in patient response to FTIs remains unclear. 
More than seventy different cellular proteins are predicted to be farnesylated (52).  
Therefore, it is likely that FTI inhibition of more than one farnesylated protein contributes to 
its anti-tumor effects.  Furthermore, it is conceivable, and even probable, that the critical FTI 
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Figure 4-3. GG-Rheb1 does not reduce FTI sensitivity of MCF-7 cells.  (A) MCF-7 cells were 
stably transfected with the  pcDNA3 empty vector or encoding wild-type Rheb1 or GG-Rheb1 
(Rheb CVLL).  Lysates of cells treated with the indicated concentrations of FTI-2153 were probed 
with antibodies to Rheb1 and β-actin (loading control).  FTI induced a mobility shift in wild-type 
Rheb1, but not in GG-Rheb1.  (B) MCF-7 stable cell lines were seeded in replicates of 8 in 96-well 
plates and treated with DMSO or the indicated concentration of FTI-2153 for 3 days.  Cell viability 
was measured using the MTT assay.  Data represent an average of 8 replicate wells; error bars 
represent standard deviation.  (C) MCF-7 stable cells were seeded in triplicate into 0.4% soft agar 
over a 0.6% bottom layer.  After 22 days, viable colonies were stained in 2 mg/mL MTT.  ImageJ
software was used to quantify number of colonies from images of scanned plates.  Results 
represent the average of triplicate plates; error bars represent standard deviation. 
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targets for anti-tumor activity are different in different tumor types.  So how can we identify 
the targets of FTIs responsible for their anti-tumor activity in different types of tumors?  One 
approach would be to generate a shRNA library containing shRNA directed against every 
known and predicted farnesylated protein (52).  This library could then be screened to 
identify shRNAs that sensitize cells to FTI treatment.  It would be predicted that the targets 
of these shRNAs would contribute to the efficacy of FTIs.  Such studies would certainly aid 
in identifying groups of patients who may benefit from FTI therapy.  A limitation of this 
approach is that, if FTI sensitivity is based on inhibiting multiple proteins, this will not be 
mimicked by shRNA inhibition of only one substrate at a time. 
 
Is Rheb localization important for its function?  Because farnesylation is required 
for Rheb localization and signaling [Chapter 3 and  (86, 107, 114, 115, 130-132, 186)], and 
proper localization of many small GTPases, such as Ras, is required for their function (21, 
235, 236), we hypothesized that proper localization of Rheb will be required for it to function 
properly and activate mTOR.  Surprisingly, my studies in Chapter 3 found that although 
GFP-Rheb1 and GFP-Rheb2 were mislocalized in MEFs lacking Rce1 or Icmt, Rheb-induced 
activation of mTOR signaling was not impaired in these cells.  My results suggested that 
farnesylation of Rheb may be more important than proper localization for Rheb activation of 
mTOR.  However, an important caveat of these studies is that they were done using 
ectopically expressed protein.  Studies in our laboratory are underway to determine whether 
endogenous Rheb is mislocalized in MEFs lacking Rce1 or Icmt and whether endogenous 
Rheb function is impaired in these cells.  Specifically, we are planning to activate 
endogenous Rheb in these cells by using shRNA to deplete cells of the RhebGAP TSC2.  
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Knocking down TSC2 should increase endogenous S6K activation in wild-type MEFs, and 
this should be inhibited by FTI.  Based on my studies in Chapter 3, I predict that knocking 
down TSC2 will also increase Rheb activity and S6K activation in Rce1- and Icmt-deficient 
cells, whereas FTI will prevent this increase.  These results would be consistent with my 
studies, where I found that a farnesylation-defective Rheb mutant could not activate S6K in 
Rce1- or Icmt-deficient cells, whereas farnesylated Rheb strongly induced S6K activation 
(Figure 3-4A).  If we indeed confirm that endogenous Rheb localization, but not activity, is 
impaired in the absence of Rce1 or Icmt, it would suggest that perhaps Rheb farnesylation is 
required for interaction with effectors such as PLD1 or mTOR (90, 91).  For example, Ras 
farnesylation is required for its interaction with galectin-1 (63).  Notably, Rheb farnesylation 
is not required for binding to and inhibition of B-Raf (109).  It will be interesting to 
determine whether Rheb inhibition of aggresome formation is dependent on farnesylation or 
post-prenyl processing. 
 My studies suggest that Icmt and Rce1 inhibitors will not block Rheb activation of 
mTOR.  However, it will be important to test this in vivo.  Mice deficient in Icmt or Rce1 in 
specific tissues have been generated (56, 58); will crossing a transgenic mouse model 
overexpressing Rheb (113, 118) to these mice impair Rheb-induced tumor growth?  These in 
vivo studies will more definitively determine whether Rheb post-prenyl processing is 
required for Rheb-induced oncogenesis. 
 
Can more selective Rheb inhibitors be developed?  As mentioned above, cells 
contain dozens of farnesylated proteins, and even more proteins are modified by Icmt and 
Rce1.  Therefore, inhibitors of CAAX-mediated posttranslational processing are not expected 
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to be specific for Rheb and may exhibit numerous off-target and potentially deleterious side 
effects.  For example, as discussed in Chapter 1, the tumor suppressor ARHI is farnesylated 
(149).  Hence, FTIs may inhibit the tumor suppressive function of ARHI.  Thus, if Rheb is 
proven to be a good target for anti-cancer therapeutics, it will be critical to develop more 
specific inhibitors of Rheb that do not block other farnesylated proteins. 
How can more specific Rheb inhibitors be designed?  One possibility is to use the 
yeast 2-hybrid system to screen for small molecules that disrupt Rheb association with 
mTOR or PLD-1.  Such a screen has been described to identify small molecule inhibitors of 
Ras association with its effector Raf-1 (237).  However, such small molecule inhibitors may 
not prevent Rheb association with effectors other than PLD-1 or mTOR.  Once a GEF for 
Rheb is identified, another possible approach is to find small molecules that inhibit the 
exchange activity of this GEF (238, 239), or that prevent Rheb binding to its GEF, similar to 
the small molecule NSC23766, which inhibits the interaction of Rac with the GEFs Trio and 
Tiam1 (240).  A third approach may be to block Rheb GTP binding.  Such an approach has 
not been deemed feasible for most small GTPases due to extremely high affinities for GTP.  
Nevertheless, studies from our lab have shown that the small molecule Rac inhibitor EHT 
1864 displaces the guanine nucleotide from Rac and inhibits its downstream signaling (241).  
Currently, small molecules that displace guanine nucleotides from other small GTPases have 
not yet been identified. 
 Recently, hyperactive Rheb was shown to sensitize cells to apoptosis induced by 
proteasome inhibitors due to the inability to form aggresomes (112).  Therefore, proteasome 
inhibitors or other agents that promote accumulation of misfolded proteins may represent an 
indirect way to inhibit the growth of Rheb-dependent tumors.  The proteasome inhibitor 
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bortezomib (Velcade®) is FDA-approved for the treatment of multiple myeloma and is 
currently in clinical trials in solid tumors in combination with various chemotherapeutics 
(www.clinicaltrials.gov).  Indeed, bortezomib was shown to preferentially induce apoptosis 
in the livers of TSC1-deficient mice (112), suggesting that it may be a useful therapy for 
tuberous sclerosis and other tumors harboring hyperactive Rheb.  More studies are needed to 
determine whether bortezomib blocks Rheb-induced oncogenesis in vivo. 
 
Rheb versus mTOR: which is a better therapeutic target?  Since relatively 
selective mTORC1 inhibitors already exist and exhibit some clinical benefit (136), is it 
practical to pursue Rheb inhibitors for cancer treatment?  Several lines of evidence suggest 
that Rheb inhibition may be clinically relevant and may even be superior to mTOR inhibition 
under certain circumstances.  First, in tuberous sclerosis, Rheb activation is more directly 
linked to loss of TSC1 or TSC2 function; mTORC1 activation in these cells is most likely a 
result of Rheb activation.  Rapamycin and rapamycin analogs are currently in clinical trials 
for tuberous sclerosis-associated malignancies, such as angiomyolipoma kidney tumors and 
the lung disease lymphangioleiomyomatosis (LAM) (242).  While such therapy did reduce 
tumor volume, in some cases up to 50-75%, the tumors did not disappear, and regrowth 
occurred in the year of follow-up off therapy (242).  Furthermore, in one clinical trial, 
rapamycin treatment did not significantly improve lung function in patients with LAM (242).  
Therefore, these conditions are far from cured with mTOR inhibitors. 
FTI has been shown to reduce S6 phosphorylation, cell viability, and soft agar growth 
in TSC1- and TSC2-deficient MEFs (131).  Whether FTI also inhibits the growth of tuberous 
sclerosis patient-derived tumor cell lines, such as the TRI-101 renal angiomyolipoma cell 
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line harboring a loss-of-function mutation in TSC2 (243), should be determined.  
Furthermore, to directly compare whether Rheb inhibition would be superior to mTORC1 
inhibition in these cells, shRNA could be used to knock down either raptor (to exclusively 
inhibit mTORC1) or the combination of Rheb1 and Rheb2 in TRI-101 cells, and the 
tumorigenic potential of these cells could be tested.  If Rheb inhibition is found to be superior 
to mTOR inhibition, and if FTIs inhibit the growth of TRI-101 cells, then perhaps FTIs 
should be considered for tuberous sclerosis clinical trials. 
A second line of evidence suggesting that Rheb inhibitors may be advantageous under 
certain circumstances is that numerous studies have detected Rheb overexpression or 
amplification in a variety of cancers (114-118), while similar mTOR aberrations have not 
been reported.  Thus, Rheb inhibitors may be more beneficial in these cancers. 
Finally, Rheb may have mTOR-independent functions that contribute to 
tumorigenesis, such as inhibition of aggresome formation (112).  Other as-yet-unidentified 
downstream effectors of Rheb may also contribute to its oncogenic activity, independently of 
mTOR.  An analogy could be drawn to Ras-induced oncogenesis, where it is thought that 
multiple downstream effectors contribute to Ras-driven tumor formation (38).  Whether Rheb 
functions in a similar manner has not been determined. 
Inhibition of Rheb may also be therapeutically beneficial in diseases other than 
tuberous sclerosis and cancer.  For example, since Rheb inhibits aggresome formation, it may 
be an attractive therapeutic target for diseases associated with misfolded proteins (112), such 
as cystic fibrosis and Parkinson’s disease (244).  Since this function of Rheb is independent 
of mTOR, rapamycin analogs would not be expected to be as efficacious as Rheb inhibitors. 
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Does FTS inhibit mTOR-dependent tumor growth?  My studies in Chapter 3 
found that FTS potently blocked mTOR activation of S6K in cellulo.  Future work should be 
aimed at whether FTS also inhibits mTOR signaling and mTOR-dependent tumor growth in 
vivo.  Does FTS impair the growth of TSC2-deficient cells, such as TRI-101 
angiomyolipoma cells, in vitro and in vivo?  Does FTS, like rapamycin, inhibit Rheb-induced 
transformation of chick embryo fibroblasts (114), or Rheb-induced oncogenesis in vivo (113, 
118)?  Does FTS promote autophagy, like other mTOR inhibitors (245)?    It will also be 
important to test whether FTS treatment reduces phospho-S6K and phospho-4EBP1 in vivo, 
and whether S6K or 4E-BP1 phosphorylation should be used as biomarkers to predict patient 
response.  However, some tumors with high phospho-S6K levels may harbor S6K 
amplification, which has been observed in a subset of breast cancers (246, 247), and would 
be predicted to impart resistance to mTOR inhibitors; perhaps the combination of high S6K 
and 4E-BP1 phosphorylation would be most predictive.  Finally, my studies found that 
another farnesyl-containing small molecule, TLN-4601, also blocks mTOR activation of S6K 
(Figure 4-4).  Thus, TLN-4601 should be included in the above studies to determine whether 
it behaves similarly to FTS. 
FTS may be particularly efficacious in breast cancer.  Santen and colleagues found 
that FTS inhibited the growth of hormone-dependent breast cancer cells and reduced 
antiestrogen resistance (77, 78, 248, 249).  It will be important to determine whether, like 
rapamycin analogs, FTS synergizes with endocrine therapies and HER2 inhibitors in the 
clinic. 
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Figure 4-4. Inhibition of mTOR signaling by farnesyl-containing small molecules.  (A) NIH 
3T3 cells were transiently transfected with pcDNA3 vector, or with pcDNA3 encoding HA-tagged K-
Ras G12V, FLAG-tagged Rheb1 N153T, or AU1-tagged mTOR E2419K, along with pRK7 HA-
tagged S6K1, and serum- and amino acid-starved.  Cell lysates were resolved by SDS-PAGE and 
immunoblotted with antibodies to phospho-S6K or β-actin (loading control).  (B) MCF-7 cells 
growing in complete medium were treated with 100 μM FTS or 30 μM TLN-4601 for 0, 3, 6, 16, or 
24 h.  Cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies to phospho-
S6K (pS6K), phospho-AKT (pAKT), phospho-ERK (pERK), or β-actin (loading control).  
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Comparison of FTS to other mTOR inhibitors.  In addition to rapamycin analogs 
(“rapalogs”), mTOR kinase inhibitiors (“TORKinibs”) have also entered clinical studies.  
Figure 4-5 summarizes the mTOR inhibitors currently under clinical evaluation for cancer 
treatment.  Unlike rapalogs, TORKinibs inhibit the kinase activity of both mTORC1 and the 
rapamycin-insensitive mTOR complex mTORC2, which phosphorylates AKT.  Recent 
studies have suggested that mTORC2 may contribute to oncogenesis independently of 
mTORC1 (250, 251).  TORKinibs were also shown to inhibit mTORC1 activity more 
completely than rapalogs (252).  Since FTS did not inhibit AKT phosphorylation at Ser 473 
(the site phosphorylated by mTORC2) (Figure 4-4), FTS is not expected to inhibit mTORC2. 
 Although two rapalogs have been FDA-approved for the treatment of renal cell 
carcinoma, the success of rapalogs has been limited due to several factors.  First, side effects 
associated with treatment with rapalogs include immunosuppression, mucositis, fatigue, and 
thrombocytopenia (253).  Second, the identification of an appropriate patient population that 
will benefit from mTOR inhibition has been daunting (136).  A third problem with mTORC1 
inhibition is the elimination of a negative feedback loop which dampens PI3K-AKT 
signaling (Figure 4-6).  Normally, S6K phosphorylates and inactivates IRS-1, resulting in a 
decrease in AKT phosphorylation and AKT-mediated cell survival signaling (254-256).  
Rapalogs prevent this feedback inhibition; hence, patients treated with rapalogs exhibit 
increased levels of phospho-AKT (255), which promotes tumor cell survival.  In addition, 
treatment with rapalogs also results in increased levels of phospho-ERK by similar 
elimination of a negative feedback loop (257, 258).  These events may promote resistance to 
rapamycin and its derivatives. 
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Figure 4-5. Inhibitors of the Rheb-mTOR pathway in clinical trials.  The primary classes of 
mTOR inhibitors are rapamycin analogs, or “rapalogs,” which target mTORC1 alone, and mTOR 
kinase inhibitors, or “TORKinibs,” which target both mTORC1 and mTORC2.  Two rapalogs, 
everolimus and temsirolimus, have recently been FDA-approved for the treatment of kidney 
cancer.  Some TORKinibs also inhibit the structurally related lipid kinase PI3K.  My studies in 
Chapter 3 validated farnesyl-containing small molecules such as salirasib (FTS) as a distinct class 
of mTOR inhibitors.  Adapted from Petroulakis et al., Br J Canc 2006;94:195-9. 
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 FTS may overcome some of these feedback problems.  If FTS blocks both mTOR and 
Ras activity, then FTS would be expected to prevent the upregulation of ERK 
phosphorylation in response to mTORC1 inhibition (Figure 4-6).  A dual Ras/mTORC1 
inhibitor would be particularly attractive and may have broader efficacy than an inhibitor of 
either mTORC1 or Ras alone. 
 
What are the targets of FTS required for its anti-tumor activity?  As with FTI, 
determining the key targets of FTS responsible for its anti-tumor activity will be crucial in 
order to identify an appropriate patient population that may benefit from FTS therapy.  
Identification of the key targets will also provide a reliable biomarker to monitor FTS activity 
in order to validate that target inhibition is achieved in the patient.  It is conceivable that 
inhibition of Ras, mTOR, or perhaps both is responsible for FTS anti-tumor activity.  
Alternatively, an as yet unidentified target of FTS may mediate its anti-tumor effects.  To 
determine whether Ras inhibition contributes to FTS anti-tumor activity, Ras inhibition may 
be rescued by expression of myristylated Ras, which is predicted to be resistant to FTS 
inhibition (62).  If cells expressing myristylated Ras remain sensitive to FTS, this would 
suggest that Ras is probably not the most important FTS target.  To determine if mTOR 
inhibition contributes to FTS activity, overexpression of both mTOR and raptor may prevent 
FTS inhibition of mTOR-raptor binding (79), and the sensitivity of these cells to FTS may 
then be assessed.  Another potential approach would be to knock down mTOR or raptor 
using shRNA and determine whether this synergizes with FTS treatment.  If these approaches 
fail to identify the appropriate target(s) of FTS, then genome-wide shRNA screens may be 
used to identify genes that, when downregulated, result in synthetic lethality in combination 
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Figure 4-6. Feedback regulation of mTOR signaling.  The mTOR substrate S6K phosphorylates
and inhibits the adaptor protein IRS1, thereby blocking PI3K signaling to AKT and Ras.  
Repression of S6K activation by rapamycin relieves this negative regulation, leading to increased 
levels of AKT and ERK phosphorylation in rapamycin-treated tumors.  FTS may prevent 
upregulation of ERK upon mTORC1 inhibition by also blocking Ras signaling.  Adapted from 
Carracedo et al., J Clin Invest 2008;118:3065-74. 
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with FTS treatment (259).  These experiments will assist in determining which patients will 
benefit most from FTS therapy. 
 
Summary.  Although protein kinase inhibitors continue to be the favored avenue for 
anti-cancer drug discovery, it is also acknowledged that this pipeline is finite and that we 
may soon reach the limits of this approach.  Therefore, there is considerable discussion and 
debate in the pharmaceutical industry regarding what the next “big” classes of molecules will 
be for targeted therapeutics.  One such class of molecules is the Ras superfamily of small 
GTPases.  While my studies have added to the knowledge of the function of Ras family small 
GTPases in breast cancer, much remains to be determined.  These studies argue against a role 
for Rerg as a tumor suppressor in breast cancer, but future studies should determine whether 
Rerg is involved in breast or other cancers in vivo.  Although Rheb has also been implicated 
in breast cancer, the precise role Rheb plays in breast cancer progression remains to be 
defined.  I investigated several strategies to block Rheb signaling in cancer and found that 
FTS potently blocks mTOR activation.  Since FTS is currently undergoing clinical 
evaluation, this work has significant implications for the selection of patients that may 
benefit from FTS.  Much more regarding the functions of Ras family small GTPases in breast 
cancer biology remains to be discovered, but such studies will likely lead to improved breast 
cancer therapeutics and patient treatment. 
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